Author: "Tarantini, Giuseppe" / Database: OpenAIRE - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Tarantini, Giuseppe"' showing total 216 results

Start Over Author "Tarantini, Giuseppe" Database OpenAIRE

216 results on '"Tarantini, Giuseppe"'

1. Management of coronary artery disease in patients undergoing transcatheter aortic valve implantation. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions in collaboration with the ESC Working Group on Cardiovascular Surgery

Author: Tarantini, Giuseppe, Tang, Gilbert, Nai Fovino, Luca, Blackman, Daniel, Van Mieghem, Nicolas M., Kim, Won-Keun, Karam, Nicole, Carrilho-Ferreira, Pedro, Fournier, Stephane, Pręgowski, Jerzy, Fraccaro, Chiara, Vincent, Flavien, Campante Teles, Rui, Mylotte, Darren, Wong, Ivan, Bieliauskas, Gintautas, Czerny, Martin, Bonaros, Nikolaos, Parolari, Alessandro, Dudek, Darius, Tchetche, Didier, Eltchaninoff, Hélène, de Backer, Ole, Stefanini, Giulio, Sondergaard, Lars, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), Cardiology, Cardiothoracic Surgery, and Repositório da Universidade de Lisboa
Subjects: TAVI, Coronary arterydisease, SDG 3 - Good Health and Well-being, Aortic stenosis, Cardiology and Cardiovascular Medicine
Abstract: © Europa Digital & Publishing 2023. All rights reserved, Significant coronary artery disease (CAD) is a frequent finding in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI), and the management of these two conditions becomes of particular importance with the extension of the procedure to younger and lower-risk patients. Yet, the preprocedural diagnostic evaluation and the indications for treatment of significant CAD in TAVI candidates remain a matter of debate. In this clinical consensus statement, a group of experts from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in collaboration with the European Society of Cardiology (ESC) Working Group on Cardiovascular Surgery aims to review the available evidence on the topic and proposes a rationale for the diagnostic evaluation and indications for percutaneous revascularisation of CAD in patients with severe aortic stenosis undergoing transcatheter treatment. Moreover, it also focuses on commissural alignment of transcatheter heart valves and coronary re-access after TAVI and redo-TAVI.
Published: 2023

2. Prediction of mortality and heart failure hospitalisations in patients undergoing M-TEER: external validation of the COAPT risk score

Author: Adamo, Marianna, Rubbio, Antonio Popolo, Zaccone, Gregorio, Pighi, Michele, Massussi, Mauro, Tomasoni, Daniela, Pancaldi, Edoardo, Testa, Luca, Tusa, Maurizio B, De Marco, Federico, Giannini, Cristina, Grasso, Carmelo, De Felice, Francesco, Denti, Paolo, Godino, Cosmo, Mongiardo, Annalisa, Crimi, Gabriele, Villa, Emmanuel, Monteforte, Ida, Citro, Rodolfo, Giordano, Arturo, Bertorelli, Antonio L, Petronio, Anna Sonia, Chizzola, Giuliano, Tarantini, Giuseppe, Tamburino, Corrado, Bedogni, Francesco, and Metra, Marco
Subjects: Cardiology and Cardiovascular Medicine
Published: 2023

3. Vascular Access in Patients With Peripheral Arterial Disease Undergoing TAVR: The Hostile Registry

Author: Palmerini, Tullio, Saia, Francesco, Kim, Won Keun, Renker, Matthias, Iadanza, Alessandro, Fineschi, Massimo, Bruno, Antonio Giulio, Ghetti, Gabriele, Vanhaverbeke, Maarten, Søndergaard, Lars, De Backer, Ole, Romagnoli, Enrico, Burzotta, Francesco, Trani, Carlo, Adrichem, Rik, Van Mieghem, Nicolas M., Nardi, Elena, Chietera, Francesco, Orzalkiewicz, Mateusz, Tomii, Daijiro, Pilgrim, Thomas, Aranzulla, Tiziana Claudia, Musumeci, Giuseppe, Adam, Matti, Meertens, Max M., Taglieri, Nevio, Marrozzini, Cinzia, Alvarez Covarrubias, Hector Alfonso, Joner, Michael, Nardi, Giulia, Di Muro, Francesca Maria, Di Mario, Carlo, Loretz, Lucca, Toggweiler, Stefan, Gallitto, Enrico, Gargiulo, Mauro, Testa, Luca, Bedogni, Francesco, Berti, Sergio, Ancona, Marco B., Montorfano, Matteo, Leone, Alessandro, Savini, Carlo, Pacini, Davide, Gmeiner, Jonas, Braun, Daniel, Nerla, Roberto, Castriota, Fausto, De Carlo, Marco, Petronio, Anna Sonia, Barbanti, Marco, Costa, Giuliano, Tamburino, Corrado, Leone, Pier Pasquale, Reimers, Bernhard, Stefanini, Giulio, Sudo, Mitsumasa, Nickenig, Georg, Piva, Tommaso, Scotti, Andrea, Latib, Azeem, Vercellino, Matteo, Porto, Italo, Codner, Pablo, Kornowski, Ran, Bartorelli, Antonio L., Tarantini, Giuseppe, Fraccaro, Chiara, Abdel-Wahab, Mohamed, Grube, Eberhard, Galié, Nazzareno, Stone, Gregg W., and Cardiology
Abstract: Background: The optimal access route in patients with severe peripheral artery disease (PAD) undergoing transcatheter aortic valve replacement (TAVR) remains undetermined. Objectives: This study sought to compare clinical outcomes with transfemoral access (TFA), transthoracic access (TTA), and nonthoracic transalternative access (TAA) in TAVR patients with severe PAD. Methods: Patients with PAD and hostile femoral access (TFA impossible, or possible only after percutaneous treatment) undergoing TAVR at 28 international centers were included in this registry. The primary endpoint was the propensity-adjusted risk of 30-day major adverse events (MAE) defined as the composite of all-cause mortality, stroke/transient ischemic attack (TIA), or main access site–related Valve Academic Research Consortium 3 major vascular complications. Outcomes were also stratified according to the severity of PAD using a novel risk score (Hostile score). Results: Among the 1,707 patients included in the registry, 518 (30.3%) underwent TAVR with TFA after percutaneous treatment, 642 (37.6%) with TTA, and 547 (32.0%) with TAA (mostly transaxillary). Compared with TTA, both TFA (adjusted HR: 0.58; 95% CI: 0.45-0.75) and TAA (adjusted HR: 0.60; 95% CI: 0.47-0.78) were associated with lower 30-day rates of MAE, driven by fewer access site–related complications. Composite risks at 1 year were also lower with TFA and TAA compared with TTA. TFA compared with TAA was associated with lower 1-year risk of stroke/TIA (adjusted HR: 0.49; 95% CI: 0.24-0.98), a finding confined to patients with low Hostile scores (Pinteraction = 0.049). Conclusions: Among patients with PAD undergoing TAVR, both TFA and TAA were associated with lower 30-day and 1-year rates of MAE compared with TTA, but 1-year stroke/TIA rates were higher with TAA compared with TFA.
Published: 2023

4. design and rationale of the BASELINE trial

Author: Nuis, Rutger Jan, van Belle, Eric, Teles, Rui, Blackman, Daniel, Veulemans, Verena, Santos, Ignacio Amat, Pilgrim, Thomas, Tarantini, Giuseppe, Saia, Francesco, Iakovou, Ioannis, Mascherbauer, Julia, Vincent, Flavien, Geleijnse, Marcel, Sathananthan, Janarthanan, Wood, David, Makkar, Raj, Van Mieghem, Nicolas M., and NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
Subjects: Cardiology and Cardiovascular Medicine
Abstract: Funding Information: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Publisher Copyright: © 2022 The Author(s) Background: Surgical aortic valve bioprostheses may degenerate over time and require redo intervention. Transcatheter aortic valve replacement (TAVR) is a less invasive alternative to redo surgery. The BAlloon Expandable vs. SElf Expanding Transcatheter VaLve for Degenerated BioprosthesIs (BASELINE) trial was designed to compare the performance of the balloon-expandable SAPIEN-3 Ultra and the self-expanding EVOLUT PRO+ valve systems in symptomatic patients with a failing surgical bioprosthesis. Methods: The BASELINE trial is an investigator-initiated, non-funded, prospective, randomized, open-label, superiority trial enrolling a total of 440 patients in up to 50 sites in 12 countries in Europe and North-America. The primary endpoint is device success at 30-days defined by the Valve Academic Research Consortium-3 Criteria as the composite of technical success, freedom from mortality, freedom for surgery or intervention related to the device or to a major vascular or access-related or cardiac structural complication with an intended performance of the valve (mean gradient
Published: 2023

5. Patent foramen ovale occlusion with the Cocoon PFO Occluder. The PROS-IT collaborative project

Author: Testa, Luca, Popolo Rubbio, Antonio, Squillace, Mattia, Albano, Flavio, Cesario, Vincenzo, Casenghi, Matteo, Tarantini, Giuseppe, Pagnotta, Paolo, Ielasi, Alfonso, Popusoi, Grigore, Paloscia, Leonardo, Durante, Alessandro, Maffeo, Diego, Meucci, Francesco, Valentini, Giuliano, Ussia, Gian Paolo, Cioffi, Paolo, Cortese, Bernardo, Sangiorgi, Giuseppe, Contegiacomo, Gaetano, and Bedogni, Francesco
Subjects: embolism, nanoparticle, patent foramen ovale (PFO), platinum, translational, Cardiology and Cardiovascular Medicine
Abstract: BackgroundThe Cocoon patent foramen ovale (PFO) Occluder is a new generation nitinol alloy double-disk device coated with nanoplatinum, likely useful in patients with nickel hypersensitivity. Early results and mid-term outcomes of this device in percutaneous PFO closure are missing.AimsTo assess the preliminary efficacy and safety profile of PFO closure with Cocoon device in an Italian multi-center registry.MethodsThis is a prospective registry of 189 consecutive adult patients treated with the Cocoon PFO Occluder at 15 Italian centers from May 2017 till May 2020. Patients were followed up for 2 years.ResultsClosure of the PFO with Cocoon Occluder was carried out successfully in all patients, with complete closure without residual shunt in 94.7% of the patients and minimal shunt in 5.3%. Except from a case of paroxysmal supraventricular tachycardia and a major vascular bleeding, no procedural and in-hospital device-related complications occurred. No patient developed cardiac erosions, allergic reactions to nickel, or any other major complications during the follow-up. During the follow-up period, 2 cases of new-onset atrial fibrillation occurred within thirty-day.ConclusionsPercutaneous closure of PFO with Cocoon Occluder provided satisfactory procedural and mid-term clinical follow-up results in a real-world registry.
Published: 2023
Full Text: View/download PDF

6. Updated definition of pulmonary hypertension and outcome after transcatheter aortic valve implantation

Author: Cardaioli, Francesco, Nai Fovino, Luca, Fabris, Tommaso, Masiero, Giulia, Arturi, Federico, Trevisanello, Aurora, Zuccarelli, Vittorio, Napodano, Massimo, Fraccaro, Chiara, Continisio, Saverio, and Tarantini, Giuseppe
Subjects: aortic stenosis, transcatheter aortic valve replacement
Published: 2023

7. Sex, Antithrombotics, and Outcomes After TAVR: Is There More Difference Within Sexes or Between Them?

Author: Masiero, Giulia and Tarantini, Giuseppe
Subjects: antithrombotic therapy, aortic stenosis, sex, transcatheter aortic valve replacement, bleeding
Published: 2023

8. Impact of vascular complications after transcatheter aortic valve implantation. VASC-OBSERVANT II sub-study

Author: Aurigemma, Cristina, Trani, Carlo, D'Errigo, Paola, Barbanti, Marco, Biancari, Fausto, Tarantini, Giuseppe, Santoro, Gennaro, Baiocchi, Massimo, Baglio, Giovanni, Seccareccia, Fulvia, and Rosato, Stefano
Subjects: TAVI, vascular complications, femoral approach, aortic stenosis, bleeding
Published: 2023

9. Cardiac Amyloidosis in Patients With Severe Aortic Stenosis: Not a Good Reason to Say No to Transcatheter Aortic Valve Implantation

Author: Tarantini, Giuseppe and Nai Fovino, Luca
Published: 2023

10. Predictors of target lesion failure after treatment of left main, bifurcation, or chronic total occlusion lesions with ultrathin-strut drug-eluting coronary stents in the ULTRA registry

Author: de Filippo, Ovidio, Bruno, Francesco, Pinxterhuis, Tineke H, Gąsior, Mariusz, Perl, Leor, Gaido, Luca, Tuttolomondo, Domenico, Greco, Antonio, Verardi, Roberto, Lo Martire, Gianluca, Iannaccone, Mario, Leone, Attilio, Liccardo, Gaetano, Caglioni, Serena, González Ferreiro, Rocio, Rodinò, Giulio, Musumeci, Giuseppe, Patti, Giuseppe, Borzillo, Irene, Tarantini, Giuseppe, Wańha, Wojciech, Casella, Bruno, Ploumen, Eline H, Pyka, Łukasz, Kornowski, Ran, Gagnor, Andrea, Piccolo, Raffaele, Roubin, Sergio Raposeiras, Capodanno, Davide, Zocca, Paolo, Conrotto, Federico, De Ferrari, Gaetano M, von Birgelen, Clemens, and D'Ascenzo, Fabrizio
Subjects: chronic total occlusion, coronary bifurcation, drug-eluting stents, left main disease, percutaneous coronary intervention (PCI)
Published: 2023

11. [SICI-GISE/SICOA Consensus document: Clinical follow-up of patients after acute coronary syndrome or percutaneous coronary intervention]

Author: Guarini, Pasquale, Saia, Francesco, Sidiropulos, Milena, Silverio, Angelo, Dellegrottaglie, Santo, Scatteia, Alessandra, De Stefano, Francesco, Tedeschi, Carlo, Dalla Vecchia, Laura A., Cappelletti, Alberto M., Regazzoli, Damiano, Benassi, Alberto, Donatelli, Francesco, America, Raffaella, Nosso, Gabriella, Capranzano, Piera, Oliva, Angelo, Piccolo, Raffaele, Testa, Luca, Attisano, Tiziana, Battistina, Castiglioni, Contarini, Marco, De Marco, Federico, Fineschi, Massimo, Menozzi, Alberto, Musto, Carmine, Stefanini, Giulio, Tarantini, Giuseppe, Caiazza, Francesco, and Esposito, Giovanni
Published: 2023

12. 2-year outcomes of MitraClip as a bridge to heart transplantation: The international MitraBridge registry

Author: Munafò, Andrea Raffaele, Scotti, Andrea, Estévez-Loureiro, Rodrigo, Adamo, Marianna, Hernàndez, Antonio Portolés, Peregrina, Estefanìa Fernàndez, Gutierrez, Lola, Taramasso, Maurizio, Fam, Neil P, Edwin C, Ho, Asgar, Anita, Vitrella, Giancarlo, Raineri, Claudia, Chizzola, Giuliano, Pezzola, Elisa, Le Ruz, Robin, Montalto, Claudio, Oreglia, Jacopo A, Fraccaro, Chiara, Giannini, Cristina, Fiorelli, Francesca, Rubbio, Antonio Popolo, Ooms, J F, Compagnone, Miriam, Marcelli, Chiara, Maffeo, Diego, Bettari, Luca, Fürholz, Monika, Arzamendi, Dabit, Guerin, Patrice, Tamburino, Corrado, Petronio, A Sonia, Grasso, Carmelo, Agricola, Eustachio, Van Mieghem, Nicolas M, Tarantini, Giuseppe, Praz, Fabien, Pascual, Isaac, Potena, Luciano, Colombo, Antonio, Maisano, Francesco, Metra, Marco, Margonato, Alberto, Crimi, Gabriele, Saia, Francesco, and Godino, Cosmo
Subjects: Advanced heart failure, Heart transplantation, MitraClip, Secondary mitral regurgitation, Transcatheter mitral valve intervention, 610 Medicine & health
Abstract: BACKGROUND In the first report from the MitraBridge registry, MitraClip as a bridge to heart transplantation (HTx) proved to be at 1-year an effective treatment strategy for 119 patients with advanced heart failure (HF) who were potential candidates for HTx. We aimed to determine if benefits of MitraClip procedure as a bridge-to-transplant persist up to 2-years. METHODS By the end of the enrollment period, a total of 153 advanced HF patients (median age 59 years, left ventricular ejection fraction 26.9 ± 7.7%) with significant secondary mitral regurgitation, who were potential candidates for HTx and were treated with MitraClip as a bridge-to-transplant strategy, were included in the MitraBridge registry. The primary endpoint was the 2-year composite adverse events rate of all-cause death, first hospitalization for HF, urgent HTx or LVAD implantation. RESULTS Procedural success was achieved in 89.5% of cases. Thirty-day mortality was 0%. At 2-year, Kaplan-Meier estimates of freedom from primary endpoint was 47%. Through 24 months, the annualized rate of HF rehospitalization per patient-year was 44%. After an overall median follow-up time of 26 (9-52) months, elective HTx was successfully performed in 30 cases (21%), 19 patients (13.5%) maintained or obtained the eligibility for transplant, and 32 patients (22.5%) no longer had an indication for HTx because of significant clinical improvement. CONCLUSIONS After 2-years of follow-up, the use of MitraClip as a bridge-to-transplant was confirmed as an effective strategy, allowing elective HTx or eligibility for transplant in one third of patients, and no more need for transplantation in 22.5% of cases.
Published: 2023

13. Vascular Access in Patients With Peripheral Arterial Disease Undergoing TAVR: The Hostile Registry

Author: Palmerini, Tullio, Saia, Francesco, Kim, Won-Keun, Renker, Matthias, Iadanza, Alessandro, Fineschi, Massimo, Bruno, Antonio Giulio, Ghetti, Gabriele, Vanhaverbeke, Maarten, Søndergaard, Lars, De Backer, Ole, Romagnoli, Enrico, Burzotta, Francesco, Trani, Carlo, Adrichem, Rik, Van Mieghem, Nicolas M, Nardi, Elena, Chietera, Francesco, Orzalkiewicz, Mateusz, Tomii, Daijiro, Pilgrim, Thomas, Aranzulla, Tiziana Claudia, Musumeci, Giuseppe, Adam, Matti, Meertens, Max M, Taglieri, Nevio, Marrozzini, Cinzia, Alvarez Covarrubias, Hector Alfonso, Joner, Michael, Nardi, Giulia, Di Muro, Francesca Maria, Di Mario, Carlo, Loretz, Lucca, Toggweiler, Stefan, Gallitto, Enrico, Gargiulo, Mauro, Testa, Luca, Bedogni, Francesco, Berti, Sergio, Ancona, Marco B, Montorfano, Matteo, Leone, Alessandro, Savini, Carlo, Pacini, Davide, Gmeiner, Jonas, Braun, Daniel, Nerla, Roberto, Castriota, Fausto, De Carlo, Marco, Petronio, Anna Sonia, Barbanti, Marco, Costa, Giuliano, Tamburino, Corrado, Leone, Pier Pasquale, Reimers, Bernhard, Stefanini, Giulio, Sudo, Mitsumasa, Nickenig, Georg, Piva, Tommaso, Scotti, Andrea, Latib, Azeem, Vercellino, Matteo, Porto, Italo, Codner, Pablo, Kornowski, Ran, Bartorelli, Antonio L, Tarantini, Giuseppe, Fraccaro, Chiara, Abdel-Wahab, Mohamed, Grube, Eberhard, Galié, Nazzareno, and Stone, Gregg W
Subjects: alternative access, critical patient, femoral access, transcatheter aortic valve replacement, Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, 610 Medicine & health
Abstract: BACKGROUND The optimal access route in patients with severe peripheral artery disease (PAD) undergoing transcatheter aortic valve replacement (TAVR) remains undetermined. OBJECTIVES This study sought to compare clinical outcomes with transfemoral access (TFA), transthoracic access (TTA), and nonthoracic transalternative access (TAA) in TAVR patients with severe PAD. METHODS Patients with PAD and hostile femoral access (TFA impossible, or possible only after percutaneous treatment) undergoing TAVR at 28 international centers were included in this registry. The primary endpoint was the propensity-adjusted risk of 30-day major adverse events (MAE) defined as the composite of all-cause mortality, stroke/transient ischemic attack (TIA), or main access site-related Valve Academic Research Consortium 3 major vascular complications. Outcomes were also stratified according to the severity of PAD using a novel risk score (Hostile score). RESULTS Among the 1,707 patients included in the registry, 518 (30.3%) underwent TAVR with TFA after percutaneous treatment, 642 (37.6%) with TTA, and 547 (32.0%) with TAA (mostly transaxillary). Compared with TTA, both TFA (adjusted HR: 0.58; 95% CI: 0.45-0.75) and TAA (adjusted HR: 0.60; 95% CI: 0.47-0.78) were associated with lower 30-day rates of MAE, driven by fewer access site-related complications. Composite risks at 1 year were also lower with TFA and TAA compared with TTA. TFA compared with TAA was associated with lower 1-year risk of stroke/TIA (adjusted HR: 0.49; 95% CI: 0.24-0.98), a finding confined to patients with low Hostile scores (Pinteraction = 0.049). CONCLUSIONS Among patients with PAD undergoing TAVR, both TFA and TAA were associated with lower 30-day and 1-year rates of MAE compared with TTA, but 1-year stroke/TIA rates were higher with TAA compared with TFA.
Published: 2023

14. Applied coronary physiology for planning and guidance of percutaneous coronary interventions. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology

Author: Escaned, Javier, Berry, Colin, De Bruyne, Bernard, Shabbir, Asad, Collet, Carlos, Lee, Joo Myung, Appelman, Yolande, Barbato, Emanuele, Biscaglia, Simone, Buszman, Piotr P, Campo, Gianluca, Chieffo, Alaide, Colleran, Róisín, Collison, Damien, Davies, Justin E, Giacoppo, Daniele, Holm, Niels R, Jeremias, Allen, Paradies, Valeria, Piróth, Zsolt, Raposo, Luís, Roguin, Ariel, Rudolph, Tanja, Sarno, Giovanna, Sen, Sayan, Toth, Gabor G, Van Belle, Eric, Zimmermann, Frederick M, Dudek, Dariusz, Stefanini, Giulio, Tarantini, Giuseppe, Cardiology, ACS - Atherosclerosis & ischemic syndromes, and ACS - Microcirculation
Abstract: The clinical value of fractional flow reserve and non-hyperaemic pressure ratios are well established in determining an indication for percutaneous coronary intervention (PCI) in patients with coronary artery disease (CAD). In addition, over the last 5 years we have witnessed a shift towards the use of physiology to enhance procedural planning, assess post-PCI functional results, and guide PCI optimisation. In this regard, clinical studies have reported compelling data supporting the use of longitudinal vessel analysis, obtained with pressure guidewire pullbacks, to better understand how obstructive CAD contributes to myocardial ischaemia, to establish the likelihood of functionally successful PCI, to identify the presence and location of residual flow-limiting stenoses and to predict long-term outcomes. The introduction of new functional coronary angiography tools, which merge angiographic information with fluid dynamic equations to deliver information equivalent to intracoronary pressure measurements, are now available and potentially also applicable to these endeavours. Furthermore, the ability of longitudinal vessel analysis to predict the functional results of stenting has played an integral role in the evolving field of simulated PCI. Nevertheless, it is important to have an awareness of the value and challenges of physiology-guided PCI in specific clinical and anatomical contexts. The main aim of this European Association of Percutaneous Cardiovascular Interventions clinical consensus statement is to offer up-to-date evidence and expert opinion on the use of applied coronary physiology for procedural PCI planning, disease pattern recognition and post-PCI optimisation.
Published: 2023

15. Prognostic Significance of Flail Mitral Leaflet in Transcatheter Edge-to-Edge Repair for Primary Mitral Regurgitation

Author: Tusa, Maurizio, Popolo Rubbio, Antonio, Sisinni, Antonio, Borin, Andrea, Barletta, Marta, Grasso, Carmelo, Adamo, Marianna, Denti, Paolo, Giordano, Arturo, De Marco, Federico, Bartorelli, Antonio L, Montorfano, Matteo, Godino, Cosmo, Citro, Rodolfo, De Felice, Francesco, Mongiardo, Annalisa, Monteforte, Ida, Villa, Emmanuel, Petronio, Anna Sonia, Giannini, Cristina, Munafò, Andrea Raffaele, Crimi, Gabriele, Tarantini, Giuseppe, Testa, Luca, Tamburino, Corrado, and Bedogni, Francesco
Published: 2023

16. Acute Reduction in Left Ventricular Function Following Transcatheter Mitral Edge-to-Edge Repair

Author: Perl, Leor, Kheifets, Mark, Guido, Ascione, Agricola, Eustachio, Denti, Paolo, Wild, Mirjam Gauri, Praz, Fabien, Rubbio, Antonio Popolo, Bedogni, Francesco, De Marco, Federico, Beeri, Ronen, Shuvy, Mony, Melillo, Francesco, Montorfano, Matteo, Freixa, Xavier, de la Fuente Mancera, Juan Carlos, Giordano, Arturo, Finizio, Filippo, Van Mieghem, Nicolas M, Ooms, J F W, Fam, Neil, O'Connor, Cormac, Toggweiler, Stefan, Levi, Amos, Shapira, Yaron, Schwartzenberg, Shmuel, Pidello, Stefano, D'Ascenzo, Fabrizio, Angelini, Filippo, Haberman, Dan, Crimi, Gabriele, Porto, Italo, Cozzi, Ottavia, Giannini, Francesco, Tarantini, Giuseppe, Maisano, Francesco, and Kornowski, Ran
Subjects: 610 Medicine & health, left ventricular ejection fraction, mitral regurgitation, afterload mismatch
Abstract: Background Little is known about the impact of transcatheter mitral valve edge-to-edge repair on changes in left ventricular ejection fraction (LVEF) and the effect of an acute reduction in LVEF on prognosis. We aimed to assess changes in LVEF after transcatheter mitral valve edge-to-edge repair for both primary and secondary mitral regurgitation (PMR and SMR, respectively), identify rates and predictors of LVEF reduction, and estimate its impact on prognosis. Methods and Results In this international multicenter registry, patients with both PMR and SMR undergoing transcatheter mitral valve edge-to-edge repair were included. We assessed rates of acute LVEF reduction (LVEFR), defined as an acute relative decrease of >15% in LVEF, its impact on all-cause mortality, major adverse cardiac event (composite end point of all-cause death, mitral valve surgery, and residual mitral regurgitation grade ≥2), and LVEF at 12 months, as well as predictors for LVEFR. Of 2534 patients included (727 with PMR, and 1807 with SMR), 469 (18.5%) developed LVEFR. Patients with PMR were older (79.0±9.2 versus 71.8±8.9 years; P
Published: 2023
Full Text: View/download PDF

17. Redo Aortic Valve Interventions: A Good Start Is Half the Job to Subsequent Permutations

Author: Tarantini, Giuseppe and Fabris, Tommaso
Subjects: aortic stenosis, surgical aortic valve, transcatheter aortic valve replacement
Published: 2023

18. A prospective study comparing short versus standard dual antiplatelet therapy in patients with acute myocardial infarction: design and rationale of the TARGET-FIRST trial

Author: Tarantini, Giuseppe, Smits, Peter Cornelius, Lhermusier, Thibault, Honton, Benjamin, Rangé, Grégoire, Piot, Christophe, Lemesle, Gilles, Ruiz Nodar, Juan Miguel, Godin, Matthieu, Madera Cambero, Maria, Motreff, Pascal, Cuisset, Thomas, Bouchez, David, Poezevara, Yann, and Cayla, Guillaume
Published: 2023

19. A large, prospective, multicentre study of left main PCI using a latest-generation zotarolimus-eluting stent: the ROLEX study

Author: Tarantini, Giuseppe, Fovino, Luca Nai, Varbella, Ferdinando, Trabattoni, Daniela, Caramanno, Giuseppe, Trani, Carlo, De Cesare, Nicoletta, Esposito, Giovanni, Montorfano, Matteo, Musto, Carmine, Picchi, Andrea, Sheiban, Imad, Gasparetto, Valeria, Ribichini, Flavio L, Cardaioli, Francesco, Saccà, Salvatore, Cerrato, Enrico, Napodano, Massimo, Martinato, Matteo, Azzolina, Danila, Andò, Giuseppe, Mugnolo, Antonio, Caruso, Marco, Rossini, Roberta, Passamonti, Enrico, Teles, Rui Campante, Rigattieri, Stefano, Gregori, Dario, Tamburino, Corrado, and Burzotta, Francesco
Subjects: cardiovascular disease, Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, pci, stent, heart disease, Cardiology and Cardiovascular Medicine
Abstract: Data on left main (LM) percutaneous coronary interventions (PCI) have mostly been obtained in studies using drug-eluting stent (DES) platforms without dedicated large-vessel devices and with limited expansion capability.Our study aimed to investigate the safety and efficacy of LM PCI with the latest-generation Resolute Onyx DES.ROLEX (Revascularization Of LEft main with resolute onyX) is a prospective, multicentre study (ClinicalTrials.gov: NCT03316833) enrolling patients with unprotected LM coronary artery disease and a SYNTAX score33 undergoing PCI with the Resolute Onyx zotarolimus-eluting coronary stent, that includes dedicated extra-large vessel platforms. The primary endpoint (EP) was target lesion failure (TLF): a composite of cardiac death, target vessel myocardial infarction (TVMI) and ischaemia-driven target lesion revascularisation (ID-TLR), at 1 year. All events were adjudicated by an independent clinical event committee. An independent core lab analysed all procedural angiograms.A total of 450 patients (mean age 71.8 years, SYNTAX score 24.5±7.2, acute coronary syndrome in 53%) were enrolled in 26 centres. Of these, 77% of subjects underwent PCI with a single-stent and 23% with a 2-stent technique (8% double kissing [DK] crush, 6% culotte, 9% T/T and small protrusion [TAP] stenting). Intravascular imaging guidance was used in 45% (42% intravascular ultrasound [IVUS], 3% optical coherence tomography [OCT]). At 1 year, the primary EP incidence was 5.1% (cardiac death 2.7%, TVMI 2.7%, ID-TLR 2.0%). The definite/probable stent thrombosis rate was 1.1%. In a prespecified adjusted subanalysis, the primary EP incidence was significantly lower in patients undergoing IVUS/OCT-guided versus angio-guided PCI (2.0 vs 7.6%; hazard ratio [HR] 0.28, 95% confidence interval [CI]: 0.13-0.58; p0.001).In this large, multicentre, prospective registry, LM PCI with the Resolute Onyx DES showed good safety and efficacy at 1 year, particularly when guided by intracoronary imaging.
Published: 2022

20. Institutional re-evolution of mitral valve procedures

Author: Ponzoni, Matteo, Fiocco, Alessandro, Caraffa, Raphael, Nadali, Matteo, Longinotti, Lorenzo, Pradegan, Nicola, Bifulco, Olimpia, Besola, Laura, Fovino, Luca Nai, Tarantini, Giuseppe, Colli, Andrea, and Gerosa, Gino
Published: 2022

21. Prevalence and Prognostic Impact of Carotid Artery Disease in Patients Undergoing TAVI

Author: Lepidi, Sandro, Squizzato, Francesco, Fovino, Luca Nai, D'Oria, Mario, Badawy, Mostafa Rabea, Fraccaro, Chiara, Antonello, Michele, Tarantini, Giuseppe, Lepidi, Sandro, Squizzato, Francesco, Fovino, Luca Nai, D'Oria, Mario, Badawy, Mostafa Rabea, Fraccaro, Chiara, Antonello, Michele, and Tarantini, Giuseppe
Subjects: Stroke, TAVI, Carotid artery disease, Carotid artery stenting, Carotid endarterectomy
Abstract: Objective: To assess the prevalence of atherosclerotic carotid artery disease (ACAD) in patients undergoing transcatheter aortic valve implantation (TAVI) and postoperative cerebrovascular and evaluate its prognostic impact on post-operative cerebrovascular incidents (CVA). Methods: Retrospective review of all consecutive patients with severe symptomatic aortic valve stenosis (AVS) who underwent TAVI at a single tertiary university hospital (January 2008-December 2018). Patients with AVS scheduled for TAVI and concomitant carotid stenosis were evaluated for prophylactic carotid revascularization (carotid endarterectomy, CEA or carotid artery stenting, CAS). Results: 771 consecutive patients (mean age 80 years, 52% males), were treated by TAVI procedures. Carotid stenosis >70% was detected in 69 patients (9%); it was unilateral in 47 (68%) and bilateral in 22 (32%). Prophylactic carotid revascularization was performed before TAVI in 45 patients (31%): in 63.1% of patients (30/47) with unilateral carotid stenosis >70%, and in 68.1% (15/22) with bilateral carotid stenosis >70%. Postoperative CVA following TAVI procedures were recorded in 25 patients (3.2%): 22 cases of stroke (2.8%) and 3 cases of transient ischemic attack (0.4%). At multiple logistic regression, only bilateral carotid stenosis >70% (OR 1.16, CI 95% 1.03-1.31; p=.0009) was found as independent predictors of periprocedural CVA. Conclusions: In patients with severe symptomatic AVS undergoing TAVI, carotid stenosis was frequently observed. Unilateral carotid stenosis >70% did not show a significant association with early CVA following TAVI. However, in the cohort of patients with bilateral carotid stenosis >70%, a significant association with postoperative CVA was observed.
Published: 2022

22. Center Valve Preference and Outcomes of Transcatheter Aortic Valve Replacement: Insights From the AMTRAC Registry

Author: Witberg, Guy, Landes, Uri, Talmor-Barkan, Yeela, Richter, Ilan, Barbanti, Marco, Valvo, Roberto, De Backer, Ole, Ooms, Joris F., Islas, Fabian, Marroquin, Luis, Sedaghat, Alexander, Sugiura, Atsushi, Masiero, Giulia, Armario, Xavier, Fiorina, Claudia, Arzamendi, Dabit, Santos-Martinez, Sandra, Fernández-Vázquez, Felipe, Baz, Jose A., Steblovnik, Klemen, Mauri, Victor, Adam, Matti, Merdler, Ilan, Hein, Manuel, Ruile, Philipp, Codner, Pablo, Grasso, Carmelo, Branca, Luca, Estévez-Loureiro, Rodrigo, Benito-González, Tomás, Amat-Santos, Ignacio J., Mylotte, Darren, Bunc, Matjaz, Tarantini, Giuseppe, Nombela-Franco, Luis, Søndergaard, Lars, Van Mieghem, Nicolas M., Finkelstein, Ariel, Kornowski, Ran, and Cardiology
Abstract: Background: Data on outcomes of transcatheter aortic valve replacement (TAVR) using balloon-expandable valves (BEVs) or self-expandable valves (SEVs) as well as the impact of center valve preference on these outcomes are limited. Objectives: The aim of this study was to compare outcomes of TAVR procedures using third-generation BEVs and SEVs stratified by center valve preference. Methods: In a multicenter registry (n = 17), 13 centers exhibited valve preference (66.6%-90% of volume) and were included. Outcomes were compared between BEVs and SEVs stratified by center valve preference. Results: In total, 7,528 TAVR procedures (3,854 with SEVs and 3,674 with BEVs) were included. The mean age was 81 years, and the mean Society of Thoracic Surgeons score was 5.2. Baseline characteristics were similar between BEVs and SEVs. Need for pacemaker implantation was higher with SEVs at BEV- and SEV-dominant centers (17.8% vs 9.3% [P < 0.001] and 12.7% vs 10.0% [P = 0.036], respectively; HR: 1.51; P for interaction = 0.021), risk for cerebrovascular accident was higher with SEVs at BEV-dominant but not SEV-dominant centers (3.6% vs 1.1% [P < 0.001] and 2.2% vs 1.4% [P = 0.162]; HR: 2.08; P for interaction < 0.01). Aortic regurgitation greater than mild was more frequent with SEVs at BEV-dominant centers and similar with BEVs regardless of center dominance (5.2% vs 2.8% [P < 0.001] and 3.4% vs 3.7% [P = 0.504], respectively). Two-year mortality was higher with SEVs at BEV-dominant centers but not at SEV-dominant centers (21.9% vs 16.9% [P = 0.021] and 16.8% vs 16.5% [P = 0.642], respectively; HR: 1.20; P for interaction = 0.032). Conclusions: Periprocedural outcomes, aortic regurgitation greater than mild, and 2-year mortality are worse when TAVR is performed using SEVs at BEV-dominant centers. Outcomes are similar regardless of valve type at SEV-dominant centers. The present results stress the need to account for this factor when comparing BEV and SEV outcomes. (The Aortic+Mitral Transcatheter [AMTRAC] Valve Registry; NCT04031274)
Published: 2022

23. Advanced stage Hodgkin Lymphoma: patient management

Author: Gini, Guido, Cimminiello, Michele, Galieni, Piero, Hohaus, Stefan, Nassi, Luca, Picardi, Marco, Romano, Alessandra, and Tarantini, Giuseppe
Subjects: Adult, Male, Young Adult, Hodgkin Lymphoma, How I Treat, Humans, Female, advanced stage, first-line treatment, Hodgkin Disease, Aged, Neoplasm Staging
Abstract: Hodgkin lymphoma (HL) is a rare cancer of the lymphoid system. It clinically presents with swollen lymph nodes and/or systemic symptoms, such as fever, night sweats, or weight loss, as signs of a more advanced stage disease. For the purpose of treatment allocation, HL cases are classified as early-stage favorable, early-stage unfavorable, and advanced-stage disease. Here below we describe four different clinical cases from real life that address some key issues and medical needs that are present in the daily practice with patients affected by advanced stage HL. The four clinical cases are quite heterogeneous, but in each case there are strong inputs to manage a specific category of advanced phase HL patient that is going to be treated with first-line therapy.
Published: 2020

24. Outcomes of 10,312 patients treated with everolimus-eluting bioresorbable scaffolds during daily clinical practice – results from the European Absorb Consortium

Author: Wiebe, Jens, Hofmann, Felix J., West, Nick, Baumbach, Andreas, Carrie, Didier, Bermudez, Eduardo Pinar, Cayla, Guillaume, Hernandez, Felipe Hernandez, Torre Hernandez, Jose M., Koning, René, Loi, Bruno, Moscarella, Elisabetta, Tarantini, Giuseppe, Zaman, Azfar, Lober, Christiane, Riemer, Thomas, Achenbach, Stephan, Hamm, Christian W., Nef, Holger M., and Justus Liebig University Giessen
Subjects: ddc:610
Published: 2022
Full Text: View/download PDF

25. sj-docx-1-acr-10.1177_02841851211061438 - Supplemental material for Patient exposure dose in interventional cardiology per clinical and technical complexity levels. Part 1: results of the VERIDIC project

Author: Feghali, Joelle Ann, Delépierre, Julie, Belac, Olivera Ciraj, Dabin, Jérémie, Deleu, Marine, De Monte, Francesca, Dobric, Milan, Gallagher, Aoife, Hadid-Beurrier, Lama, Henry, Patrick, Hršak, Hrvoje, Kiernan, Tom, Kumar, Rajesh, Knežević, Željka, Maccia, Carlo, Majer, Marija, Malchair, Françoise, Noble, Stéphane, Obrad, Davor, Sans Merce, Marta, Sideris, Georgios, Simantirakis, George, Spaulding, Christian, Tarantini, Giuseppe, and Van Ngoc Ty, Claire
Subjects: 110320 Radiology and Organ Imaging, FOS: Clinical medicine
Abstract: Supplemental material, sj-docx-1-acr-10.1177_02841851211061438 for Patient exposure dose in interventional cardiology per clinical and technical complexity levels. Part 1: results of the VERIDIC project by Joelle Ann Feghali, Julie Delépierre, Olivera Ciraj Belac, Jérémie Dabin, Marine Deleu, Francesca De Monte, Milan Dobric, Aoife Gallagher, Lama Hadid-Beurrier, Patrick Henry, Hrvoje Hršak, Tom Kiernan, Rajesh Kumar, Željka Knežević, Carlo Maccia, Marija Majer, Françoise Malchair, Stéphane Noble, Davor Obrad, Marta Sans Merce, Georgios Sideris, George Simantirakis, Christian Spaulding, Giuseppe Tarantini and Claire Van Ngoc Ty in Acta Radiologica
Published: 2022
Full Text: View/download PDF

26. Center Valve Preference and Outcomes of Transcatheter Aortic Valve Replacement: Insights From the AMTRAC Registry

Author: Witberg, Guy, Landes, Uri, Talmor-Barkan, Yeela, Richter, Ilan, Barbanti, Marco, Valvo, Roberto, De Backer, Ole, Ooms, Joris F, Islas, Fabian, Marroquin, Luis, Sedaghat, Alexander, Sugiura, Atsushi, Masiero, Giulia, Armario, Xavier, Fiorina, Claudia, Arzamendi, Dabit, Santos-Martinez, Sandra, Fernández-Vázquez, Felipe, Baz, Jose A, Steblovnik, Klemen, Mauri, Victor, Adam, Matti, Merdler, Ilan, Hein, Manuel, Ruile, Philipp, Codner, Pablo, Grasso, Carmelo, Branca, Luca, Estévez-Loureiro, Rodrigo, Benito-González, Tomás, Amat-Santos, Ignacio J, Mylotte, Darren, Bunc, Matjaz, Tarantini, Giuseppe, Nombela-Franco, Luis, Søndergaard, Lars, Van Mieghem, Nicolas M, Finkelstein, Ariel, and Kornowski, Ran
Subjects: Aortic Valve Insufficiency, aortic stenosis, self-expandable valve, Aortic Valve Stenosis, TAVR, Prosthesis Design, balloon-expandable valve, Aged, 80 and over, Aortic Valve, Humans, Registries, Risk Factors, Treatment Outcome, Heart Valve Prosthesis, Transcatheter Aortic Valve Replacement, 80 and over, Aged
Published: 2022

27. [Left main percutaneous coronary intervention using zotarolimus-eluting stent: data from the ROLEX registry]

Author: Barioli, Alberto, D'Agosta, Guido, Ruggiero, Rossella, Demola, Pierluigi, Nai Fovino, Luca, Tarantini, Giuseppe, and Masiero, Giulia
Published: 2022

28. Transcatheter Aortic Valve Replacement With Self-Expanding ACURATE neo2: Postprocedural Hemodynamic and Short-Term Clinical Outcomes

Author: Buono, Andrea, Gorla, Riccardo, Ielasi, Alfonso, Costa, Giuliano, Cozzi, Ottavia, Ancona, Marco, Soriano, Francesco, De Carlo, Marco, Ferrara, Erica, Giannini, Francesco, Massussi, Mauro, Fovino, Luca Nai, Pero, Gaetano, Bettari, Luca, Acerbi, Elena, Messina, Antonio, Sgroi, Carmelo, Pellicano, Mariano, Sun, Jinwei, Gallo, Francesco, Franchina, Antonio Gabriele, Bruno, Francesco, Nerla, Roberto, Saccocci, Matteo, Villa, Emmanuel, D'Ascenzo, Fabrizio, Conrotto, Federico, Cuccia, Claudio, Tarantini, Giuseppe, Fiorina, Claudia, Castriota, Fausto, Poli, Arnaldo, Petronio, Anna Sonia, Oreglia, Jacopo, Montorfano, Matteo, Regazzoli, Damiano, Reimers, Bernhard, Tamburino, Corrado, Tespili, Maurizio, Bedogni, Francesco, Barbanti, Marco, and Maffeo, Diego
Subjects: Aortic Valve Insufficiency, Hemodynamics, SE THV, Aortic Valve Stenosis, TAVR, Prosthesis Design, aortic regurgitation, Transcatheter Aortic Valve Replacement, Treatment Outcome, ACURATE neo2, paravalvular leak, Aortic Valve, Heart Valve Prosthesis, self-expanding THV, Humans, Retrospective Studies
Abstract: The first-generation ACURATE neo transcatheter heart valve (THV) (Boston Scientific) was associated with a non-negligible occurrence of moderate or greater paravalvular aortic regurgitation (AR) following transcatheter aortic valve replacement. To overcome this issue, the ACURATE neo2 iteration, which incorporates a taller outer skirt aimed at reducing the occurrence of paravalvular AR, has recently been developed.The aim of this study was to assess the efficacy and safety of the ACURATE neo2 (Boston Scientific) THV in patients with severe aortic valve stenosis.ITAL-neo was an observational, retrospective, multicenter registry enrolling consecutive patients with severe aortic valve stenosis, treated with first- and second-generation ACURATE neo THVs, via transfemoral and trans-subclavian access, in 13 Italian centers. One-to-one propensity score matching was applied to account for baseline characteristics unbalance. The primary endpoint was the occurrence of moderate or greater paravalvular AR on predischarge echocardiographic assessment. Secondary endpoints included postprocedural technical success and 90-day device success and safety.Among 900 patients included in the registry, 220 received the ACURATE neo2 THV, whereas 680 were treated with the first-generation device. A total of 410 patients were compared after 1:1 propensity score matching. The ACURATE neo2 THV was associated with a 3-fold lower frequency of postprocedural moderate or greater paravalvular AR (11.2% vs 3.5%; P 0.001). No other hemodynamic differences were observed. Postprocedural technical success was similar between the 2 cohorts. Fewer adverse events were observed in patients treated with the ACURATE neo2 at 90 days.Transfemoral transcatheter aortic valve replacement using the ACURATE neo2 was associated with a significant lower frequency of moderate or greater paravalvular AR compared with the earlier generation ACURATE neo device, with encouraging short-term safety and efficacy.
Published: 2021

29. Cardiac procedural myocardial injury, infarction, and mortality in patients undergoing elective percutaneous coronary intervention: a pooled analysis of patient-level data

Author: Silvain, Johanne, Zeitouni, Michel, Paradies, Valeria, Zheng, Huili, Ndrepepa, Gjin, Cavallini, Claudio, Feldman, Dimitri, Sharma, Samin, Mehilli, Julinda, Gili, Sebastiano, Barbato, Emanuele, Tarantini, Giuseppe, Ooi, Sze, von Birgelen, Clemens, Jaffe, Allan, Thygesen, Kristian, Montalescot, Gilles, Bulluck, Heerajnarain, Hausenloy, Derek, Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Maasstad Hospital, National University Health System [Singapore] (NUHS), Deutsches Herzzentrum München (DHM), Ospedale 'Santa Maria della Misericordia' = University Hospital 'Santa Maria della Misericordia', Weill Medical College of Cornell University [New York], Icahn School of Medicine at Mount Sinai [New York] (MSSM), Ludwig-Maximilians-Universität München (LMU), Centro Cardiologico Monzino [Milano], Dpt di Scienze Cliniche e di Comunità [Milano] (DISCCO), Università degli Studi di Milano [Milano] (UNIMI)-Università degli Studi di Milano [Milano] (UNIMI)-Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), University of Naples Federico II, University of Padua, Prince of Wales Hospital, University of Twente [Netherlands], Mayo Clinic [Rochester], Aarhus University Hospital, Norwich University, University College of London [London] (UCL), Duke-National University of Singapore Graduate Medical School, Silvain, Johanne, Zeitouni, Michel, Paradies, Valeria, Zheng, Huili L, Ndrepepa, Gjin, Cavallini, Claudio, Feldman, Dimitri N, Sharma, Samin K, Mehilli, Julinda, Gili, Sebastiano, Barbato, Emanuele, Tarantini, Giuseppe, Ooi, Sze Y, von Birgelen, Clemen, Jaffe, Allan S, Thygesen, Kristian, Montalescot, Gille, Bulluck, Heerajnarain, and Hausenloy, Derek J
Subjects: heart mortality, Procedural complication, Myocardial infarction, Elective PCI, Myocardial injury, Procedural myocardial infarction, Procedural myocardial injury, percutaneous coronary intervention, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, health care economics and organizations
Abstract: International audience; AimsThe prognostic importance of cardiac procedural myocardial injury and myocardial infarction (MI) in chronic coronary syndrome (CCS) patients undergoing elective percutaneous coronary intervention (PCI) is still debated.Methods and resultsWe analysed individual data of 9081 patients undergoing elective PCI with normal pre-PCI baseline cardiac troponin (cTn) levels. Multivariate models evaluated the association between post-PCI elevations in cTn and 1-year mortality, while an interval analysis evaluated the impact of the size of the myocardial injury on mortality. Our analysis was performed in the overall population and also according to the type of cTn used [52.0% had high-sensitivity cTn (hs-cTn)]. Procedural myocardial injury, as defined by the Fourth Universal Definition of MI (UDMI) [post-PCI cTn elevation ≥1 × 99th percentile upper reference limit (URL)], occurred in 52.8% of patients and was not associated with 1-year mortality [adj odds ratio (OR), 1.35, 95% confidence interval (CI) (0.84–1.77), P = 0.21]. The association between post-PCI cTn elevation and 1-year mortality was significant starting ≥3 × 99th percentile URL. Major myocardial injury defined by post-PCI ≥5 × 99th percentile URL occurred in 18.2% of patients and was associated with a two-fold increase in the adjusted odds of 1-year mortality [2.29, 95% CI (1.32–3.97), P = 0.004]. In the subset of patients for whom periprocedural evidence of ischaemia was collected (n = 2316), Type 4a MI defined by the Fourth UDMI occurred in 12.7% of patients and was strongly associated with 1-year mortality [adj OR 3.21, 95% CI (1.42–7.27), P = 0.005]. We also present our results according to the type of troponin used (hs-cTn or conventional troponin).ConclusionOur analysis has demonstrated that in CCS patients with normal baseline cTn levels, the post-PCI cTn elevation of ≥5 × 99th percentile URL used to define Type 4a MI is associated with 1-year mortality and could be used to detect ‘major’ procedural myocardial injury in the absence of procedural complications or evidence of new myocardial ischaemia.
Published: 2021

30. [PCSK9 inhibitor use in high cardiovascular risk patients: an interventionalist's overview on efficacy, current recommendations and factual prescription]

Author: Masiero, Giulia, Franzone, Anna, Silvestri, Tania, Castiglioni, Battistina, Greco, Francesco, La Manna, Alessio Gaetano, Limbruno, Ugo, Longoni, Matteo, Marchese, Alfredo, Mattesini, Alessio, Mauro, Ciro, Rigattieri, Stefano, Tarantino, Fabio Felice, Esposito, Giovanni, Musumeci, Giuseppe, Tarantini, Giuseppe, Masiero, Giulia, Franzone, Anna, Silvestri, Tania, Castiglioni, Battistina, Greco, Francesco, La Manna, Alessio Gaetano, Limbruno, Ugo, Longoni, Matteo, Marchese, Alfredo, Mattesini, Alessio, Mauro, Ciro, Rigattieri, Stefano, Tarantino, Fabio Felice, Esposito, Giovanni, Musumeci, Giuseppe, and Tarantini, Giuseppe
Subjects: Cardiovascular Diseases, Heart Disease Risk Factors, PCSK9 Inhibitors, Humans, Atherosclerosis, Dyslipidemias, Hypolipidemic Agents
Published: 2020

31. RENASCENT II: First in Human Evaluation of a Novel Sirolimus-Eluting Ultra-High Molecular Weight APTITUDE® Bioresorbable Scaffold: 9-and 24-Months Imaging and Clinical Results

Author: Chieffo, Alaide, Khawaja, Saud Ahmed, Latib, Azeem, Vesga, Boris, Moncada, Miguel, Delgado, Juan A, Fonseca, Jaime, Testa, Luca, Esposito, Giovanni, Ferrone, Marco, Cortese, Bernardo, Maehara, Akiko, Granada, Juan F, Colombo, Antonio, Montorfano, Matteo, Hernandez, Hector, Arana, Camilo, Dager, Antonio, Bedogni, Francesco, Stabile, Eugenio, De Benedictis, Mauro, Meliga, Emanuele, Tarantini, Giuseppe, Antoniucci, David, La Manna, Alessio, Tamburino, Corrado, Chieffo, Alaide, Khawaja, Saud Ahmed, Latib, Azeem, Vesga, Bori, Moncada, Miguel, Delgado, Juan A, Fonseca, Jaime, Testa, Luca, Esposito, Giovanni, Ferrone, Marco, Cortese, Bernardo, Maehara, Akiko, Granada, Juan F, Colombo, Antonio, Montorfano, Matteo, Hernandez, Hector, Arana, Camilo, Dager, Antonio, Bedogni, Francesco, Stabile, Eugenio, De Benedictis, Mauro, Meliga, Emanuele, Tarantini, Giuseppe, Antoniucci, David, La Manna, Alessio, and Tamburino, Corrado
Abstract: The novel sirolimus-eluting ultra-high molecular weight 115-microns strut thickness APTITUDE® Bioreabsorbable vascular scaffold (BRS) (Amaranth Medical Inc., Mountain View, CA) displays higher mechanical strength, expansion capabilities and resistance to fracture compared to clinically available BRS technologies. RENASCENT II is a prospective, multi-center first-in-human clinical study to evaluate the clinical performance of the APTITUDE® BRS in the treatment of single de novo coronary lesions among patients undergoing percutaneous coronary intervention.
Published: 2020

32. [Position paper of the Italian Society of Interventional Cardiology (SICI-GISE): Management of patent foramen ovale in patients with cerebral or systemic thromboembolism - 2020]

Author: Tarantini, Giuseppe, D'Amico, Gianpiero, Baracchini, Claudio, Berni, Andrea, Berti, Sergio, Chessa, Massimo, Esposito, Giovanni, Gaspardone, Achille, Menozzi, Alberto, Meucci, Francesco, Musumeci, Giuseppe, Onorato, Eustaquio, Rigattieri, Stefano, Saia, Francesco, Santoro, Pino, Scacciatella, Paolo, Trabattoni, Daniela, Fraccaro, Chiara, Pristipino, Cristian, Tarantini, Giuseppe, D'Amico, Gianpiero, Baracchini, Claudio, Berni, Andrea, Berti, Sergio, Chessa, Massimo, Esposito, Giovanni, Gaspardone, Achille, Menozzi, Alberto, Meucci, Francesco, Musumeci, Giuseppe, Onorato, Eustaquio, Rigattieri, Stefano, Saia, Francesco, Santoro, Pino, Scacciatella, Paolo, Trabattoni, Daniela, Fraccaro, Chiara, and Pristipino, Cristian
Abstract: Patent foramen ovale (PFO) is implicated in the pathogenesis of different clinical syndromes in which it plays variable roles. In 2017 and 2018, four randomized clinical trials were published, allowing for the clarification of certain issues pertaining to cryptogenic stroke. Recently, eight European scientific societies collaborated to the writing of an interdisciplinary international position paper on PFO and cryptogenic stroke, based upon best available evidence, with the aim of defining the principles needed to guide decision making. Nonetheless, a tailored approach is not suitably addressed by standard position documents, considering that decisions about optimal management of PFO patients with left circulation thromboembolism are often challenging, mostly due to comorbidities and complex clinical scenarios.A panel of Italian cardiology experts gathered under the auspices of the Italian Society of Interventional Cardiology (SICI-GISE) for comprehensive discussion and consensus development, with the aim of providing practical recommendations, for both clinical and interventional cardiologists, regarding optimal management of PFO in patients with cerebral or systemic thromboembolism. In this position paper, various clinical scenarios in patients with and without high-risk PFO features are presented and discussed, including PFO patients with associated conditions (e.g. hypercoagulable states, deep vein thrombosis/pulmonary embolism, short runs of atrial fibrillation), and special subsets (e.g. patients with risk factors for atrial fibrillation, patients aged ≥65 years, patients who refused percutaneous PFO closure), with the Panel's recommendations being provided for each scenario.
Published: 2020

33. Timing of Oral P2Y12 Inhibitor Administration in Non-ST Elevation Acute Coronary Syndrome

Author: Tarantini, Giuseppe, Mojoli, Marco, Varbella, Ferdinando, Caporale, Roberto, Rigattieri, Stefano, Andò, Giuseppe, Cirillo, Plinio, Pierini, Simona, Santarelli, Andrea, Sganzerla, Paolo, Cacciavillani, Luisa, Babuin, Luciano, De Cesare, Nicoletta, Limbruno, Ugo, Massoni, Alberto, Rognoni, Andrea, Pavan, Daniela, Belloni, Flavia, Cernetti, Carlo, Favero, Luca, Saia, Francesco, Fovino, Luca Nai, Masiero, Giulia, Roncon, Loris, Gasparetto, Valeria, Ferlini, Marco, Ronco, Federico, Rossini, Roberta, Canova, Paolo, Trabattoni, Daniela, Russo, Alessandra, Guiducci, Vincenzo, Penzo, Carlo, Tarantino, Fabio, Mauro, Ciro, Corrada, Elena, Esposito, Giovanni, Berti, Sergio, Martinato, Matteo, Azzolina, Danila, Gregori, Dario, Angiolillo, Dominick J, Musumeci, Giuseppe, Tarantini, Giuseppe, Mojoli, Marco, Varbella, Ferdinando, Caporale, Roberto, Rigattieri, Stefano, Andò, Giuseppe, Cirillo, Plinio, Pierini, Simona, Santarelli, Andrea, Sganzerla, Paolo, Cacciavillani, Luisa, Babuin, Luciano, De Cesare, Nicoletta, Limbruno, Ugo, Massoni, Alberto, Rognoni, Andrea, Pavan, Daniela, Belloni, Flavia, Cernetti, Carlo, Favero, Luca, Saia, Francesco, Fovino, Luca Nai, Masiero, Giulia, Roncon, Lori, Gasparetto, Valeria, Ferlini, Marco, Ronco, Federico, Rossini, Roberta, Canova, Paolo, Trabattoni, Daniela, Russo, Alessandra, Guiducci, Vincenzo, Penzo, Carlo, Tarantino, Fabio, Mauro, Ciro, Corrada, Elena, Esposito, Giovanni, Berti, Sergio, Martinato, Matteo, Azzolina, Danila, Gregori, Dario, Angiolillo, Dominick J, and Musumeci, Giuseppe
Subjects: oral P2Y12 inhibitors non-ST elevation acute coronary syndrome ischemia bleeding, oral P2Y(12) inhibitors, bleeding, ischemia, non-ST elevation acute coronary syndrome, oral P2Y12 inhibitors, non–STsegment elevation acute coronary syndrome, NO, bleeding, ischemia, non–STsegment elevation acute coronary syndrome, oral P2Y12 inhibitors
Abstract: Background Although oral P2Y12 inhibitors are key in the management of patients with non–ST-segment elevation acute coronary syndrome, the optimal timing of their administration is not well defined. Objectives The purpose of this study was to compare downstream and upstream oral P2Y12 inhibitors administration strategies in patients with non–ST-segment elevation acute coronary syndrome undergoing invasive treatment. Methods We performed a randomized, adaptive, open-label, multicenter clinical trial. Patients were randomly assigned to receive pre-treatment with ticagrelor before angiography (upstream group) or no pre-treatment (downstream group). Patients in the downstream group undergoing percutaneous coronary intervention were further randomized to receive ticagrelor or prasugrel. The primary hypothesis was the superiority of the downstream versus the upstream strategy on the combination of efficacy and safety events (net clinical benefit). Results We randomized 1,449 patients to downstream or upstream oral P2Y12 inhibitor administration. A pre-specified stopping rule for futility at interim analysis led the trial to be stopped. The rate of the primary endpoint, a composite of death due to vascular causes; nonfatal myocardial infarction or nonfatal stroke; and Bleeding Academic Research Consortium type 3, 4, and 5 bleeding through day 30, did not differ significantly between the downstream and upstream groups (percent absolute risk reduction: –0.46; 95% repeated confidence interval: –2.90 to 1.90). These results were confirmed among patients undergoing percutaneous coronary intervention (72% of population) and regardless of the timing of coronary angiography (within or after 24 h from enrollment). Conclusions Downstream and upstream oral P2Y12 inhibitor administration strategies were associated with low incidence of ischemic and bleeding events and minimal numeric difference of event rates between treatment groups. These findings led to premature interruption of the trial and suggest the unlikelihood of enhanced efficacy of 1 strategy over the other. (Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers In Non-ST Elevated Acute Coronary Syndromes With Initial Invasive Indication [DUBIUS
Published: 2020

34. Italian Society of Interventional Cardiology (GISE) Position Paper for Cath lab-specific Preparedness Recommendations for Healthcare providers in case of suspected, probable or confirmed cases of COVID-19

Author: Tarantini, Giuseppe, Fraccaro, Chiara, Chieffo, Alaide, Marchese, Alfredo, Tarantino, Fabio Felice, Rigattieri, Stefano, Limbruno, Ugo, Mauro, Ciro, La Manna, Alessio, Castiglioni, Battistina, Longoni, Matteo, Berti, Sergio, Greco, Francesco, Musumeci, Giuseppe, Esposito, Giovanni, Tarantini, Giuseppe, Fraccaro, Chiara, Chieffo, Alaide, Marchese, Alfredo, Tarantino, Fabio Felice, Rigattieri, Stefano, Limbruno, Ugo, Mauro, Ciro, La Manna, Alessio, Castiglioni, Battistina, Longoni, Matteo, Berti, Sergio, Greco, Francesco, Musumeci, Giuseppe, and Esposito, Giovanni
Subjects: Cardiac Catheterization, Infection Control, SARS-CoV-2, new coronavirus, Pneumonia, Viral, transmission, COVID-19, General Medicine, SARS Cov‐2, Betacoronavirus, healthcare protection, infections, prevention, SARS Cov-2, Clinical Protocols, Italy, Radiology Nuclear Medicine and imaging, Practice Guidelines as Topic, Humans, Cardiology and Cardiovascular Medicine, Coronavirus Infections, Core Curriculum, Pandemics, Societies, Medical
Abstract: COVID-19 pandemic raised the issue to guarantee the proper level of care to patients with acute cardiovascular diseases and concomitant suspected or confirmed COVID-19 and, in the meantime safety and protection of healthcare providers. The aim of this position paper is to provide standards to healthcare facilities and healthcare providers on infection prevention and control measures during the management of suspected and confirmed cases of 2019-nCoV infection accessing in cath-lab. The document represents the view of the Italian Society of Interventional Cardiology (GISE), and it is based on recommendations from the main World and European Health Organizations (WHO, and ECDC) as well as from the Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI). This article is protected by copyright. All rights reserved.
Published: 2020

35. Coronary Protection to Prevent Coronary Obstruction During Transcatheter Aortic Valve Replacement: A Multicenter International Registry

Author: Palmerini, Tullio, Chakravarty, Tarun, Saia, Francesco, Bruno, Antonio G, Bacchi-Reggiani, Maria-Letizia, Marrozzini, Cinzia, Patel, Chinar, Patel, Vivek, Testa, Luca, Bedogni, Francesco, Ancona, Marco, Montorfano, Matteo, Chieffo, Alaide, Olivares, Paolo, Bartorelli, Antonio L, Buscaglia, Angelo, Porto, Italo, Nickenig, Georg, Grube, Eberhard, Sinning, Jan-Malte, De Carlo, Marco, Petronio, Anna Sonia, Barbanti, Marco, Tamburino, Corrado, Iadanza, Alessandro, Burzotta, Francesco, Trani, Carlo, Fraccaro, Chiara, Tarantini, Giuseppe, Aranzulla, Tiziana C, De Benedictis, Mauro, Pagnotta, Paolo, Stefanini, Giulio G, Miura, Mizuki, Taramasso, Maurizio, Kang, Jee-Hoon, Kim, Hyo-Soo, Codner, Pablo, Kornowski, Ran, Pelliccia, Francesco, Vignali, Luigi, Taglieri, Nevio, Ghetti, Gabriele, Leone, Alessandro, Galiè, Nazzareno, Makkar, Raj, Palmerini, Tullio, Chakravarty, Tarun, Saia, Francesco, Bruno, Antonio G, Bacchi-Reggiani, Maria-Letizia, Marrozzini, Cinzia, Patel, Chinar, Patel, Vivek, Testa, Luca, Bedogni, Francesco, Ancona, Marco, Montorfano, Matteo, Chieffo, Alaide, Olivares, Paolo, Bartorelli, Antonio L, Buscaglia, Angelo, Porto, Italo, Nickenig, Georg, Grube, Eberhard, Sinning, Jan-Malte, De Carlo, Marco, Petronio, Anna Sonia, Barbanti, Marco, Tamburino, Corrado, Iadanza, Alessandro, Burzotta, Francesco, Trani, Carlo, Fraccaro, Chiara, Tarantini, Giuseppe, Aranzulla, Tiziana C, De Benedictis, Mauro, Pagnotta, Paolo, Stefanini, Giulio G, Miura, Mizuki, Taramasso, Maurizio, Kang, Jee-Hoon, Kim, Hyo-Soo, Codner, Pablo, Kornowski, Ran, Pelliccia, Francesco, Vignali, Luigi, Taglieri, Nevio, Ghetti, Gabriele, Leone, Alessandro, Galiè, Nazzareno, and Makkar, Raj
Subjects: transcatheter valve replacement, stent thrombosi, cardiovascular system, coronary obstruction
Abstract: The aim of this study was to investigate the safety and efficacy of coronary protection by preventive coronary wiring and stenting across the coronary ostia in patients at high risk for coronary obstruction after transcatheter aortic valve replacement (TAVR).
Published: 2020

36. Safety and feasibility of balloon aortic valvuloplasty in non-TAVI centers: The 'BAV for life' experience

Author: Attisano, Tiziana, Silverio, Angelo, Stabile, Eugenio, Briguori, Carlo, Tuccillo, Bernardino, Scotto Di Uccio, Fortunato, Di Lorenzo, Emilio, Tesorio, Tullio, Giordano, Arturo, Calabrò, Paolo, Cappelli Bigazzi, Maurizio, Golino, Paolo, Scherillo, Marino, Vigorito, Francesco, Quaranta, Gaetano, Esposito, Giovanni, Mauro, Ciro, Musumeci, Giuseppe, Tarantini, Giuseppe, Galasso, Gennaro, Venuti, Angela, Maione, Antongiulio, Accadia, Maria, Spadaro, Pasquale, Arnese, Maria Rosaria, Pastore, Fabio, Eusebio, Giuseppina, De Angelis, Maria Carmen, Varricchio, Attilio, Alfieri, Alfonso, Di Girolamo, Domenico, Bianchi, Renato Maria, Visconti, Gabriella, Ambrosini, Vittorio, Capasso, Michele, Formigli, Dario, Villari, Bruno, De Simone, Ciro, Manganiello, Vincenzo, Attisano, Tiziana, Silverio, Angelo, Stabile, Eugenio, Briguori, Carlo, Tuccillo, Bernardino, Scotto Di Uccio, Fortunato, Di Lorenzo, Emilio, Tesorio, Tullio, Giordano, Arturo, Calabrò, Paolo, Cappelli Bigazzi, Maurizio, Golino, Paolo, Scherillo, Marino, Vigorito, Francesco, Quaranta, Gaetano, Esposito, Giovanni, Mauro, Ciro, Musumeci, Giuseppe, Tarantini, Giuseppe, Galasso, Gennaro, Venuti, Angela, Maione, Antongiulio, Accadia, Maria, Spadaro, Pasquale, Arnese, Maria Rosaria, Pastore, Fabio, Eusebio, Giuseppina, De Angelis, Maria Carmen, Varricchio, Attilio, Alfieri, Alfonso, Di Girolamo, Domenico, Bianchi, Renato Maria, Visconti, Gabriella, Ambrosini, Vittorio, Capasso, Michele, Formigli, Dario, Villari, Bruno, De Simone, Ciro, and Manganiello, Vincenzo
Subjects: Balloon Valvuloplasty, Male, medicine.medical_specialty, Time Factors, medicine.medical_treatment, 030204 cardiovascular system & hematology, Balloon, Group B, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Nuclear Medicine and Imaging, Internal medicine, Humans, Medicine, Radiology, Nuclear Medicine and imaging, Hospital Mortality, Prospective Studies, aortic stenosis, balloon aortic valvuloplasty, transcatheter aortic valve implantation, Radiology, Nuclear Medicine and Imaging, Cardiology and Cardiovascular Medicine, 030212 general & internal medicine, Aged, Training period, Aged, 80 and over, Ejection fraction, business.industry, Cardiogenic shock, Aortic Valve Stenosis, Recovery of Function, General Medicine, aortic stenosi, medicine.disease, Aortic valvuloplasty, Treatment Outcome, Italy, Aortic valve stenosis, Heart failure, Cardiology, Feasibility Studies, Female, Radiology, business
Abstract: Objectives To evaluate the safety and the feasibility of balloon aortic valvuloplasty (BAV) procedure made by trained operators in centers not performing transcatheter aortic valve implantation (TAVI). Background BAV is a valuable therapeutic tool for patients with symptomatic severe aortic valve stenosis (AS) at prohibitive risk for TAVI or surgery. Methods Consecutive high-risk AS patients underwent BAV in five non-TAVI centers, where BAV operators had completed a 6-month training period in high-volume TAVI centers (Group A). All clinical, echocardiographic, and procedural data were prospectively collected and compared with data of patients treated in TAVI center (Group B). Results Between June 2016 and June 2017, 55 patients (83.9 ± 7.0 years) were enrolled: 25 in Group A and 30 in Group B. After BAV, a substantial reduction of the peak-to-peak aortic valve gradient was obtained in both groups (-35.3 ± 15.2 vs -28.8 ± 13.9 mmHg, P =0.25). No major bleeding or vascular complications occurred. In-hospital death was observed in three patients of Group A and two patients of Group B (P =0.493). The mean follow-up time was 303 ± 188 days; no patients were lost. The 1-year survival free from overall death (Group A 75.8% vs Group B 68.8%; P =0.682) and heart failure rehospitalization (Group A 73.0% vs Group B 66.8%; P =0.687) was similar in the two groups. At multivariable analysis, low left ventricular (LV) ejection fraction (HR: 0.943; P = 0.011) and cardiogenic shock (HR: 5.128; P = 0.002) at admission were independent predictors of mortality. Conclusions BAV is a safe and effective procedure that can be performed by trained operators in centers not performing TAVI.
Published: 2018

37. Management and Outcome of Failed Percutaneous Edge-to-Edge Mitral Valve Plasty: Insight From an International Registry

Author: Mangieri, Antonio, Melillo, Francesco, Montalto, Claudio, Denti, Paolo, Praz, Fabien, Sala, Alessandra, Winkel, Mirjam G, Taramasso, Maurizio, Tagliari, Ana Paula, Fam, Neil P, Rubbio, Antonio Popolo, De Marco, Federico, Bedogni, Francesco, Toggweiler, Stefan, Schofer, Joachim, Brinkmann, Christina, Sievert, Horst, Van Mieghem, Nicolas M, Ooms, Joris F, Paradis, Jean-Michel, Rod��s-Cabau, Josep, Brochet, Eric, Himbert, Dominique, Perl, Leor, Kornowski, Ran, Ielasi, Alfonso, Regazzoli, Damiano, Baldetti, Luca, Masiero, Giulia, Tarantini, Giuseppe, Latib, Azeem, Laricchia, Alessandra, Gattas, Angie, Tchetch��, Didier, Dumonteil, Nicolas, Francesco, Giannini, Agricola, Eustachio, Montorfano, Matteo, Lurz, Philipp, Crimi, Gabriele, Maisano, Francesco, and Colombo, Antonio
Subjects: Heart Valve Prosthesis Implantation, Cardiac Catheterization, Treatment Outcome, Humans, Mitral Valve, Mitral Valve Insufficiency, Registries, 610 Medicine & health, Retrospective Studies
Abstract: OBJECTIVES This study evaluated the incidence, management, and outcome of patients who experienced MitraClip (Abbott Vascular) failure secondary to loss of leaflet insertion (LLI), single leaflet detachment (SLD), or embolization. BACKGROUND Transcatheter edge-to-edge repair with MitraClip is an established therapy for the treatment of mitral regurgitation (MR), but no data exist regarding the prevalence and outcome according to the mode of clip failure. METHODS Between January 2009 and December 2020, we retrospectively screened 4,294 procedures of MitraClip performed in 19 centers. LLI was defined as damage to the leaflet where the MitraClip was attached, SLD as demonstration of complete separation between the device and a single leaflet tissue, and clip embolization as loss of contact between MitraClip and both leaflets. RESULTS A total of 147 cases of MitraClip failure were detected (overall incidence��=��3.5%), and these were secondary to LLI or SLD in 47 (31.9%) and 99 (67.3%) cases, respectively, whereas in 1 (0.8%) case clip embolization was observed. MitraClip failure occurred in 67 (45.5%) patients with functional MR, in 64 (43.5%) patients with degenerative MR, and 16 (10.8%) with mixed etiology. Although the majority of MitraClip failures were detected before discharge (47 intraprocedural and 42 in the hospital), up to 39.5% of cases were diagnosed at follow-up. In total, 80 (54.4%) subjects underwent a redo procedure, either percutaneously with MitraClip (n��=��51, 34.7%) or surgically (n��=��36, 24.5%) including 4 cases of surgical conversion of the index procedure and 7 cases of bailout surgery after unsuccessful redo MitraClip. After a median follow-up of 163��days (IQR: 22-720��days), 50 (43.9%) subjects presented moderate to severe MR, and 43 (29.3%) patients died. An up-front redo MitraClip strategy was associated with a trend toward a reduced rate of death at follow-up vs surgical or conservative management (P��=��0.067), whereas postprocedural acute kidney injury, age, and moderate to severe tricuspid regurgitation were independent predictors of death. CONCLUSIONS MitraClip failure secondary to LLI and SLD is not a rare phenomenon and may occur during and also beyond hospitalization. Redo MitraClip strategy demonstrates a trend toward a reduced risk of death compared with bailout surgery and conservative management. A third of those patients remained with more than moderate MR and had substantial mortality at the intermediate-term follow-up.
Published: 2021

38. Which is the best antiaggregant or anticoagulant therapy after TAVI? A propensity-matched analysis from the ITER registry. The management of DAPT after TAVI

Author: D'Ascenzo, Fabrizio, Benedetto, Umberto, Bianco, Matteo, Conrotto, Federico, Moretti, Claudio, D'Onofrio, Augusto, Agrifoglio, Marco, Colombo, Antonio, Ribichini, Flavio, Tarantini, Giuseppe, D'Amico, Maurizio, Salizzoni, Stefano, Rinaldi, Mauro, Chieffo, Alaide, Giustino, Gennaro, Regesta, Tommaso, Napodano, Massimo, Gabbieri, Davide, Saia, Francesco, Tamburino, Corrado, Cugola, Diego, Aiello, Marco, Sanna, Francesco, Iadanza, Alessandro, Pompei, Esmeralda, Stefã no, Pierluigi, Cappai, Antioco, Minati, Alessandro, Cassese, Mauro, Martinelli, Gian Luca, Agostinelli, Andrea, Fiorilli, Rosario, Casilli, Francesco, Reale, Maurizio, Bedogni, Francesco, Petronio, Anna Sonia, Omedã, Pierluigi, Montefusco, Antonio, Mozzillo, Rosa Alba, Bonmassari, Roberto, Briguori, Carlo, Liso, Armando, Sardella, Gennaro, Bruschi, Giuseppe, Gerosa, Gino, Romeo, Francesco, D'Ascenzo, Fabrizio, Benedetto, Umberto, Bianco, Matteo, Conrotto, Federico, Moretti, Claudio, D'Onofrio, Augusto, Agrifoglio, Marco, Colombo, Antonio, Ribichini, Flavio, Tarantini, Giuseppe, D'Amico, Maurizio, Salizzoni, Stefano, and Gaita, Fiorenzo
Subjects: Male, medicine.medical_specialty, Ticlopidine, Aortic stenosis, Clinical research, Transcatheter aortic valve implantation (TAVI), Cardiology and Cardiovascular Medicine, Hemorrhage, Subgroup analysis, 030204 cardiovascular system & hematology, Cohort Studies, Transcatheter Aortic Valve Replacement, 03 medical and health sciences, 0302 clinical medicine, aortic stenosis, clinical research, transcatheter aortic valve implantation (TAVI), Internal medicine, medicine, Clinical endpoint, Humans, Registries, 030212 general & internal medicine, Propensity Score, Stroke, Aged, Aged, 80 and over, Aspirin, business.industry, Clopidogrel, medicine.disease, Propensity score matching, Cardiology, Platelet aggregation inhibitor, Female, business, Platelet Aggregation Inhibitors, medicine.drug
Abstract: AIMS The safety and efficacy of single vs. dual antiplatelet therapy (DAPT) in patients undergoing TAVI remain to be addressed. The aim of our study was to evaluate the usefulness of a DAPT compared to a single platelet therapy in patients undergoing TAVI with a balloon-expandable prosthesis. METHODS AND RESULTS All consecutive patients enrolled in the ITER registry were included. Patients undergoing TAVI discharged with aspirin alone were compared to those taking DAPT before and after selection using propensity score with matching. Subgroup analysis was performed for those on OAT. Prosthetic heart valve dysfunction at follow-up was the primary endpoint, whereas all-cause death, cardiovascular death, bleedings, vascular complications and cerebrovascular accidents were the secondary ones. From 1,364 patients, after propensity score with matching, 605 were selected for each group (aspirin alone vs. DAPT). At 30 days, rates of VARC mortality were lower in patients with aspirin alone (1.5% vs. 4.1%, p=0.003), mainly driven by a reduction of major vascular complications (5.3% vs. 10.7%, p
Published: 2017

39. Performing elective cardiac invasive procedures during the COVID-19 outbreak: a position statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI): Elective cardiac invasive procedures during the COVID-19 outbreak

Author: Chieffo, Alaide, Tarantini, Giuseppe, Naber, Christoph, Barbato, Emanuele, Roffi, Marco, Stefanini, Giulio, Buchanan, Gill, Buszman, Piotr, Moreno, Raul, Zawiślak, Barbara, Cayla, Guillaume, Danenberg, Haim, Da Silveira, Joao, Nef, Holger, James, Stefan K., Mauri Ferre, Josepa, Voskuil, Michiel, Witt, Nils, Windecker, Stephan, Baumbach, Andreas, and Dudek, Dariusz
Subjects: Elective Surgical Procedures, SARS-CoV-2, Cardiovascular Surgical Procedures, Masks, COVID-19, Humans, Expert Review, Pandemics, Personal Protective Equipment
Abstract: The rearrangement of healthcare services required to face the coronavirus disease 2019 (COVID-19) pandemic led to a drastic reduction in elective cardiac invasive procedures. We are already facing a "second wave" of infections and we might be dealing during the next months with a "third wave" and subsequently new waves. Therefore, during the different waves of the COVID-19 pandemic we have to face the problems of how to perform elective cardiac invasive procedures in non-COVID patients and which patients/procedures should be prioritised. In this context, the interplay between the pandemic stage, the availability of healthcare resources and the priority of specific cardiac disorders is crucial. Clear pathways for "hot" or presumed "hot" patients and "cold" patients are mandatory in each hospital. Depending on the local testing capacity and intensity of transmission in the area, healthcare facilities may test patients for SARS-CoV-2 infection before the interventional procedure, regardless of risk assessment for COVID-19. Pre-hospital testing should always be conducted in the presence of symptoms suggestive of SARS-CoV-2 infection. In cases of confirmed or suspected COVID-19 positive patients, full personal protective equipment using FFP 2/N95 masks, eye protection, gowning and gloves is indicated during cardiac interventions for healthcare workers. When patients have tested negative for COVID-19, medical masks may be sufficient. Indeed, individual patients should themselves wear medical masks during cardiac interventions and outpatient visits.
Published: 2021

40. Position paper GISE (Società Italiana di Cardiologia Interventistica): ricovero breve per la PCI in elezione, uno strumento per la 'ripartenza'

Author: Violini, Roberto, Rosa, Salvatore, Leonardi, Sergio, Doronzo, Baldassarre, Cremonesi, Alberto, Giuditta Callea, Spandonaro, Federico, Tarantini, Giuseppe, Esposito, Giovanni, Cernetti, Carlo, Indolfi, Ciro, Berti, Sergio, Marchese, Alfredo, Saia, Francesco, and Monti, Francesco
Subjects: SAME-DAY DISCHARGE, HOSPITALIZATION, PERCUTANEOUS CORONARY INTERVENTION, HOSPITALIZATION, PERCUTANEOUS CORONARY INTERVENTION, REIMBURSEMENT, SAME-DAY DISCHARGE, REIMBURSEMENT
Published: 2021

41. Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO): impact of valve disease aetiology and residual mitral regurgitation after MitraClip implantation

Author: Bedogni, Francesco, Popolo Rubbio, Antonio, Grasso, Carmelo, Adamo, Marianna, Denti, Paolo, Giordano, Arturo, Tusa, Maurizio, Bianchi, Giovanni, De Marco, Federico, Bartorelli, Antonio L, Montorfano, Matteo, Godino, Cosmo, Citro, Rodolfo, De Felice, Francesco, Mongiardo, Annalisa, Monteforte, Ida, Villa, Emmanuel, Giannini, Cristina, Crimi, Gabriele, Tarantini, Giuseppe, Testa, Luca, and Tamburino, Corrado
Subjects: Heart Valve Prosthesis Implantation, Percutaneous mitral valve repair, GIOTTO registry, Heart failure, MitraClip, Mitral regurgitation, Humans, Italy, Registries, Treatment Outcome, Cardiology, Heart Failure, Mitral Valve Insufficiency
Abstract: The Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO) was conceived in order to assess the safety and efficacy of MitraClip therapy in Italy. The aim of this study was to assess procedural and mid-term outcomes, and clinical and echocardiographic predictors of mid-term mortality after MitraClip therapy, stratifying the results according to the diagnosis of functional and degenerative mitral regurgitation (FMR vs. DMR).Between January 2016 and March 2020, 1659 patients were prospectively included in the GIOTTO registry (FMR 59.4% vs. DMR 40.6%). Acute Mitral Valve Academic Research Consortium (MVARC) technical success was achieved in 97.2% of patients, without differences between FMR and DMR and with sustained results at 30 days. In the study population, all-cause mortality was 4.0%, 17.5% and 34.6% at 30 days, 1 year and 2 years, respectively. Cardiovascular death was the most frequent cause of mortality. Overall hospitalization rates were 6.3%, 23.4% and 31.7% at 30 days, 1 year and 2 years, respectively. The most frequent cause of hospitalization was heart failure, particularly in the first 30 days. FMR and MVARC structural and functional failure were strongly associated with 1-year mortality. Residual mitral regurgitation 1+ (rMR) was independently related to a reduced risk of 1-year mortality (hazard ratio 0.62; P = 0.005). Coherently, at 2-year follow up, FMR was associated with worse outcomes than DMR, and Kaplan-Meier all-cause mortality was related to rMR.Functional mitral regurgitation aetiology affects 1-year mortality after MitraClip implantation, and differences in mortality and hospitalization rates between FMR and DMR can be observed within 2 years. Optimal rMR 1+ was correlated to a more favourable mid-term outcome, particularly in FMR.
Published: 2021

42. COVID-19 infection in adult patients with hematological malignancies:a European Hematology Association Survey (EPICOVIDEHA)

Author: Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Verga, Luisa, Víšek, Benjamin, Ilhan, Osman, Nadali, Gianpaolo, Weinbergerová, Barbora, Córdoba-Mascuñano, Raúl, Marchetti, Monia, Collins, Graham P., Farina, Francesca, Cattaneo, Chiara, Cabirta, Alba, Gomes-Silva, Maria, Itri, Federico, van Doesum, Jaap, Ledoux, Marie-Pierre, Čerňan, Martin, Jakšić, Ozren, Duarte, Rafael F., Magliano, Gabriele, Omrani, Ali S., Fracchiolla, Nicola S., Kulasekararaj, Austin, Valković, Toni, Poulsen, Christian Bjørn, Machado, Marina, Glenthøj, Andreas, Stoma, Igor, Ráčil, Zdeněk, Piukovics, Klára, Navrátil, Milan, Emarah, Ziad, Sili, Uluhan, Maertens, Johan, Blennow, Ola, Bergantim, Rui, García-Vidal, Carolina, Prezioso, Lucia, Guidetti, Anna, del Principe, Maria Ilaria, Popova, Marina, de Jonge, Nick, Ormazabal-Vélez, Irati, Fernández, Noemí, Falces-Romero, Iker, Cuccaro, Annarosa, Meers, Stef, Buquicchio, Caterina, Antić, Darko, Al-Khabori, Murtadha, García-Sanz, Ramón, Biernat, Monika M., Tisi, Maria Chiara, Sal, Ertan, Rahimli, Laman, Čolović, Natasa, Schönlein, Martin, Calbacho, Maria, Tascini, Carlo, Miranda-Castillo, Carolina, Khanna, Nina, Méndez, Gustavo-Adolfo, Petzer, Verena, Novák, Jan, Besson, Caroline, Duléry, Rémy, Lamure, Sylvain, Nucci, Marcio, Zambrotta, Giovanni, Žák, Pavel, Seval, Guldane Cengiz, Bonuomo, Valentina, Mayer, Jiří, López-García, Alberto, Sacchi, Maria Vittoria, Booth, Stephen, Ciceri, Fabio, Oberti, Margherita, Salvini, Marco, Izuzquiza, Macarena, Nunes-Rodrigues, Raquel, Ammatuna, Emanuele, Obr, Aleš, Herbrecht, Raoul, Núñez-Martín-Buitrago, Lucía, Mancini, Valentina, Shwaylia, Hawraa, Sciumè, Mariarita, Essame, Jenna, Nygaard, Marietta, Batinić, Josip, Gonzaga, Yung, Regalado-Artamendi, Isabel, Karlsson, Linda Katharina, Shapetska, Maryia, Hanakova, Michaela, El-Ashwah, Shaimaa, Borbényi, Zita, Çolak, Gökçe Melis, Nordlander, Anna, Dragonetti, Giulia, Maraglino, Alessio Maria Edoardo, Rinaldi, Amelia, De Ramón-Sánchez, Cristina, Cornely, Oliver A., Finizio, Olimpia, Fazzi, Rita, Sapienza, Giuseppe, Chauchet, Adrien, Van Praet, Jens, Prattes, Juergen, Dargenio, Michelina, Rossi, Cédric, Shirinova, Ayten, Malak, Sandra, Tafuri, Agostino, Ommen, Hans-Beier, Bologna, Serge, Khedr, Reham Abdelaziz, Choquet, Sylvain, Joly, Bertrand, Ceesay, M. Mansour, Philippe, Laure, Kho, Chi Shan, Desole, Maximilian, Tsirigotis, Panagiotis, Otašević, Vladimir, Borducchi, Davimar M. M., Antoniadou, Anastasia, Gaziev, Javid, Almaslamani, Muna A., García-Poutón, Nicole, Paterno, Giovangiacinto, Torres-López, Andrea, Tarantini, Giuseppe, Mellinghoff, Sibylle, Gräfe, Stefanie, Börschel, Niklas, Passweg, Jakob, Merelli, Maria, Barać, Aleksandra, Wolf, Dominik, Shaikh, Mohammad Usman, Thiéblemont, Catherine, Bernard, Sophie, Funke, Vaneuza Araújo Moreira, Daguindau, Etienne, Khostelidi, Sofya, Nucci, Fabio Moore, Martín-González, Juan-Alberto, Landau, Marianne, Soussain, Carole, Laureana, Cécile, Lacombe, Karine, Kohn, Milena, Aliyeva, Gunay, Piedimonte, Monica, Fouquet, Guillemette, Rêgo, Mayara, Hoell-Neugebauer, Baerbel, Cartron, Guillaume, Pinto, Fernando, Alburquerque, Ana Munhoz, Passos, Juliana, Yilmaz, Asu Fergun, Redondo-Izal, Ana-Margarita, Altuntaş, Fevzi, Heath, Christopher, Kolditz, Martin, Schalk, Enrico, Guolo, Fabio, Karthaus, Meinolf, Della Pepa, Roberta, Vinh, Donald, Noël, Nicolas, Deau Fischer, Bénédicte, Drenou, Bernard, Mitra, Maria Enza, Meletiadis, Joseph, Bilgin, Yavuz M., Jindra, Pavel, Espigado, Ildefonso, Drgoňa, Ľuboš, Serris, Alexandra, Di Blasi, Roberta, Ali, Natasha, EPICOVIDEHA working group, [missing], Pagano, Livio, Salmanton-Garcia, Jon, Marchesi, Francesco, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Verga, Luisa, Visek, Benjamin, Ilhan, Osman, Nadali, Gianpaolo, Weinbergerova, Barbora, Cordoba-Mascunano, Raul, Marchetti, Monia, Collins, Graham P., Farina, Francesca, Cattaneo, Chiara, Cabirta, Alba, Gomes-Silva, Maria, Itri, Federico, van Doesum, Jaap, Ledoux, Marie-Pierre, Cernan, Martin, Jaksic, Ozren, Duarte, Rafael F., Magliano, Gabriele, Omrani, Ali S., Fracchiolla, Nicola S., Kulasekararaj, Austin, Valkovic, Toni, Poulsen, Christian Bjorn, Machado, Marina, Glenthoj, Andreas, Stoma, Igor, Racil, Zdenek, Piukovics, Klara, Navratil, Milan, Emarah, Ziad, Sili, Uluhan, Maertens, Johan, Blennow, Ola, Bergantim, Rui, Garcia-Vidal, Carolina, Prezioso, Lucia, Guidetti, Anna, del Principe, Maria Ilaria, Popova, Marina, de Jonge, Nick, Ormazabal-Velez, Irati, Fernandez, Noemi, Falces-Romero, Iker, Cuccaro, Annarosa, Meers, Stef, Buquicchio, Caterina, Antic, Darko, Al-Khabori, Murtadha, Garcia-Sanz, Ramon, Biernat, Monika M., Tisi, Maria Chiara, Sal, Ertan, Rahimli, Laman, Colovic, Natasa, Schonlein, Martin, Calbacho, Maria, Tascini, Carlo, Miranda-Castillo, Carolina, Khanna, Nina, Mendez, Gustavo-Adolfo, Petzer, Verena, Novak, Jan, Besson, Caroline, Dulery, Remy, Lamure, Sylvain, Nucci, Marcio, Zambrotta, Giovanni, Zak, Pavel, Seval, Guldane Cengiz, Bonuomo, Valentina, Mayer, Jiri, Lopez-Garcia, Alberto, Sacchi, Maria Vittoria, Booth, Stephen, Ciceri, Fabio, Oberti, Margherita, Salvini, Marco, Izuzquiza, Macarena, Nunes-Rodrigues, Raquel, Ammatuna, Emanuele, Obr, Ales, Herbrecht, Raoul, Nunez-Martin-Buitrago, Lucia, Mancini, Valentina, Shwaylia, Hawraa, Sciume, Mariarita, Essame, Jenna, Nygaard, Marietta, Batinic, Josip, Gonzaga, Yung, Regalado-Artamendi, Isabel, Karlsson, Linda Katharina, Shapetska, Maryia, Hanakova, Michaela, El-Ashwah, Shaimaa, Borbenyi, Zita, Colak, Gokce Melis, Nordlander, Anna, Dragonetti, Giulia, Maraglino, Alessio Maria Edoardo, Rinaldi, Amelia, De Ramon-Sanchez, Cristina, Cornely, Oliver A., Pagano, L., Salmanton-Garcia, J., Marchesi, F., Busca, A., Corradini, P., Hoenigl, M., Klimko, N., Koehler, P., Pagliuca, A., Passamonti, F., Verga, L., Visek, B., Ilhan, O., Nadali, G., Weinbergerova, B., Cordoba-Mascunano, R., Marchetti, M., Collins, G. P., Farina, F., Cattaneo, C., Cabirta, A., Gomes-Silva, M., Itri, F., van Doesum, J., Ledoux, M. -P., Cernan, M., Jaksic, O., Duarte, R. F., Magliano, G., Omrani, A. S., Fracchiolla, N. S., Kulasekararaj, A., Valkovic, T., Poulsen, C. B., Machado, M., Glenthoj, A., Stoma, I., Racil, Z., Piukovics, K., Navratil, M., Emarah, Z., Sili, U., Maertens, J., Blennow, O., Bergantim, R., Garcia-Vidal, C., Prezioso, L., Guidetti, A., del Principe, M. I., Popova, M., de Jonge, N., Ormazabal-Velez, I., Fernandez, N., Falces-Romero, I., Cuccaro, A., Meers, S., Buquicchio, C., Antic, D., Al-Khabori, M., Garcia-Sanz, R., Biernat, M. M., Tisi, M. C., Sal, E., Rahimli, L., Colovic, N., Schonlein, M., Calbacho, M., Tascini, C., Miranda-Castillo, C., Khanna, N., Mendez, G. -A., Petzer, V., Novak, J., Besson, C., Dulery, R., Lamure, S., Nucci, M., Zambrotta, G., Zak, P., Seval, G. C., Bonuomo, V., Mayer, J., Lopez-Garcia, A., Sacchi, M. V., Booth, S., Ciceri, F., Oberti, M., Salvini, M., Izuzquiza, M., Nunes-Rodrigues, R., Ammatuna, E., Obr, A., Herbrecht, R., Nunez-Martin-Buitrago, L., Mancini, V., Shwaylia, H., Sciume, M., Essame, J., Nygaard, M., Batinic, J., Gonzaga, Y., Regalado-Artamendi, I., Karlsson, L. K., Shapetska, M., Hanakova, M., El-Ashwah, S., Borbenyi, Z., Colak, G. M., Nordlander, A., Dragonetti, G., Maraglino, A. M. E., Rinaldi, A., De Ramon-Sanchez, C., Cornely, O. A., Finizio, O., Fazzi, R., Sapienza, G., Chauchet, A., Van Praet, J., Prattes, J., Dargenio, M., Rossi, C., Shirinova, A., Malak, S., Tafuri, A., Ommen, H. -B., Bologna, S., Khedr, R. A., Choquet, S., Joly, B., Ceesay, M. M., Philippe, L., Kho, C. S., Desole, M., Tsirigotis, P., Otasevic, V., Borducchi, D. M. M., Antoniadou, A., Gaziev, J., Almaslamani, M. A., Garcia-Pouton, N., Paterno, G., Torres-Lopez, A., Tarantini, G., Mellinghoff, S., Grafe, S., Borschel, N., Passweg, J., Merelli, M., Barac, A., Wolf, D., Shaikh, M. U., Thieblemont, C., Bernard, S., Funke, V. A. M., Daguindau, E., Khostelidi, S., Nucci, F. M., Martin-Gonzalez, J. -A., Landau, M., Soussain, C., Laureana, C., Lacombe, K., Kohn, M., Aliyeva, G., Piedimonte, M., Fouquet, G., Rego, M., Hoell-Neugebauer, B., Cartron, G., Pinto, F., Alburquerque, A. M., Passos, J., Yilmaz, A. F., Redondo-Izal, A. -M., Altuntas, F., Heath, C., Kolditz, M., Schalk, E., Guolo, F., Karthaus, M., Della Pepa, R., Vinh, D., Noel, N., Deau Fischer, B., Drenou, B., Mitra, M. E., Meletiadis, J., Bilgin, Y. M., Jindra, P., Espigado, I., Drgona, L., Serris, A., Di Blasi, R., Ali, N., Stem Cell Aging Leukemia and Lymphoma (SALL), Salvy-Córdoba, Nathalie, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), University Hospital of Cologne [Cologne], Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, IFO - Istituto Nazionale Tumori Regina Elena [Roma] (IRE), Città della Salute e della Scienza University-Hospital, IRCCS Istituto Nazionale dei Tumori [Milano], University of California [San Diego] (UC San Diego), University of California (UC), Medical University of Graz, Odessa National I.I.Mechnikov University, Faculty of Medicine [Cologne], University Hospital of Cologne [Cologne]-University of Cologne, King's College Hospital (KCH), Universitá degli Studi dell’Insubria = University of Insubria [Varese] (Uninsubria), Dipartimento di Medicina e Chirurgia = School of Medicine and Surgery [Monza], Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB), Faculty of Medicine in Hradec Kralove [Republique Tchèque], Charles University [Prague] (CU), Ankara University School of Medicine [Turkey], Azienda Ospedaliera Universitaria Integrata of Verona, Masaryk University [Brno] (MUNI), Fundación Jiménez Díaz, Fundacion Jimenez Diaz [Madrid] (FJD), Ospedale SS Antonio e Biagio e Cesare Arrigo, Churchill Hospital Oxford Centre for Haematology, IRCCS San Raffaele Scientific Institute [Milan, Italie], ASST Spedali Civili of Brescia, Vall d'Hebron Institute of Oncology [Barcelone] (VHIO), Vall d'Hebron University Hospital [Barcelona], Universitat Autònoma de Barcelona (UAB), Instituto Português de Oncologia de Lisboa Francisco Gentil, Ospedale San Luigi Gonzaga, University Medical Center Groningen [Groningen] (UMCG), Institut de Cancérologie de Strasbourg Europe (ICANS), Palacky University Olomouc, Zagreb School of Medicine [Zagreb, Croatia] (Dubrava University Hospital), University of Zagreb, Hospital Universitario Puerta de Hierro-Majadahonda [Madrid, Spain], ASST Great Metropolitan Niguarda / ASST Grande Ospedale Metropolitano Niguarda [Milan, Italia], Hamad Medical Corporation [Doha, Qatar], Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, University of Rijeka, Croatian Cooperative Group for Hematological Diseases (CROHEM), Zealand University Hospital [Roskilde, Denmark], Hospital General Universitario 'Gregorio Marañón' [Madrid], Department of Clinical Microbiology [Rigshospitalet], Rigshospitalet [Copenhagen], Copenhagen University Hospital-Copenhagen University Hospital, Homieĺ State Medical University (GSMU), Institute of Hematology and Blood Transfusion [Prague, Czech Republic], University of Szeged [Szeged], University Hospital Ostrava, Mansoura University [Egypt], Marmara University [Kadıköy - İstanbul], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Karolinska University Hospital [Stockholm], Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto = University of Porto, Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Hospital de São João [Porto], Faculdade de Medicina da Universidade do Porto (FMUP), Clinic Barcelona Hospital Universitari, Department of Public Health and Cell Biology, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy, Pavlov First Saint Petersburg State Medical University [St. Petersburg], Vrije Universiteit Medical Centre (VUMC), Vrije Universiteit Amsterdam [Amsterdam] (VU), Complejo Hospitalario de Navarra, Hospital Universitario Marqués de Valdecilla [Santander], La Paz University Hospital, Azienda Usl Toscana centro [Firenze], AZ Klina, Clinical Center of Serbia (KCS), University of Belgrade [Belgrade], Sultan Qaboos University Hospital, Partenaires INRAE, Hospital Universitario de Salamanca, Servicio de Haematologia, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), University of Wrocław [Poland] (UWr), San Bortolo Hospital, Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Hospital Universitario 12 de Octubre [Madrid], Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), Universidad Rey Juan Carlos [Madrid] (URJC), University of Basel (Unibas), Innsbruck Medical University = Medizinische Universität Innsbruck (IMU), University Hospital Kralovské Vinohrady, Centre Hospitalier de Versailles André Mignot (CHV), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Département Hématologie biologique [CHRU Montpellier], Pôle Biologie-Pathologie [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Universidade Federal do Estado do Rio de Janeiro (UNIRIO), San Gerardo Hospital of Monza, Oxford NIHR Biomedical Research Centre, IRCCS Ospedale San Raffaele [Milan, Italy], Assi Sette Llaghi Varese, Instituto Português de Oncologia do Porto / Portuguese Oncology Institute of Porto (IPO Porto), University Hospital Olomouc [Czech Republic], ASST Grande Ospedale Metropolitano Niguarda, University Hospital Centre Zagreb, Instituto Nacional do Câncer, Copenhagen University Hospital, Republican Scientific and Practical Center (RSPC) for organ and Tissue Transplantation, Minsk, Republican Scientific and Practical Center (RSPC) for Organ and Transplantation, German Centre for Infection Research (DZIF), Gilead Sciences, Pagano, Livio [0000-0001-8287-928X], Salmanton-García, Jon [0000-0002-6766-8297], Marchesi, Francesco [0000-0001-6353-2272], Busca, Alessandro [0000-0001-5361-5613], Corradini, Paolo [0000-0002-9186-1353], Hoenigl, Martin [0000-0002-1653-2824], Klimko, Nikolay [0000-0001-6095-7531], Koehler, Philipp [0000-0002-7386-7495], Pagliuca, Antonio [0000-0003-2519-0333], Passamonti, Francesco [0000-0001-8068-5289], Verga, Luisa [0000-0003-1142-8435], Víšek, Benjamin [0000-0001-8268-452X], Ilhan, Osman [0000-0003-1665-372X], Weinbergerová, Barbora [0000-0001-6460-2471], Córdoba, Raúl [0000-0002-7654-8836], Marchetti, Monia [0000-0001-7615-0572], Farina, Francesca [0000-0002-5124-6970], Cattaneo, Chiara [0000-0003-0031-3237], Cabirta, Alba [0000-0001-7198-8894], Gomes-Silva, Maria [0000-0002-6993-2450], Itri, Federico [0000-0002-3532-5281], Doesum, Jaap van [0000-0003-0214-3219], Ledoux, Marie-Pierre [0000-0002-3261-3616], Čerňan, Martin [0000-0003-2345-1229], Jakšić, Ozren [0000-0003-4026-285X], Magliano, Gabriel [0000-0002-9129-1530], Omrani, Ali S. [0000-0001-5309-6358], Fracchiolla, Nicola S. [0000-0002-8982-8079], Kulasekararaj, Austin G. [0000-0003-3180-3570], Valković, Toni [0000-0001-6083-8815], Poulsen, Christian Bjørn [0000-0001-9785-1378], Machado, Marina [0000-0002-8370-2248], Glenthøj, Andrea [0000-0003-2082-0738], Stoma, Igor [0000-0003-0483-7329], Ráčil, Zdeněk [0000-0003-3511-4596], Piukovics, Klára [0000-0003-4480-3131], Emarah, Ziad [0000-0003-0622-2598], Sili, Uluhan [0000-0002-9939-9298], Maertens, Johan [0000-0003-4257-5980], Bergantim, Rui [0000-0002-7811-9509], García-Vidal, Carolina [0000-0002-8915-0683], Prezioso, Lucia [0000-0003-1660-4960], Principe, Maria Ilaria del [0000-0002-3958-0669], Popova, Marina [0000-0001-8536-5495], Jonge, Nick de [0000-0002-9901-0887], Ormazabal-Vélez, Irati [0000-0003-1141-5546], Falces-Romero, Iker [0000-0001-5888-7706], Cuccaro, Annarosa [0000-0002-0237-1839], Meers, Stef [0000-0003-1754-2175], Buquicchio, Caterina [0000-0002-3683-5953], Antić, Darko [0000-0002-2608-1342], Al-Khabori, Murtadha [0000-0002-2937-8838], García-Sanz, Ramón [0000-0003-4120-2787], Biernat, Monika [0000-0003-3161-3398], Tisi, Maria Chiara [0000-0001-8231-6700], Sal, Ertan [0000-0003-2761-2675], Rahimli, Laman [0000-0003-2266-445X], Schönlein, Martin [0000-0002-1010-0975], Calbacho, María [0000-0001-8106-4863], Tascini, Carlo [0000-0001-9625-6024], Miranda-Castillo, Carolina [0000-0001-8763-9576], Khanna, Nina [0000-0002-2642-419X], Méndez, Gustavo-Adolfo [0000-0003-0514-7004], Petzer, Verena [0000-0002-9205-1440], Besson, Caroline [0000-0003-4364-7173], Duléry, Rémy [0000-0002-5024-1713], Lamure, Sylvain [0000-0001-5980-305X], Nucci, Marcio [0000-0003-4867-0014], Zambrotta, Giovanni [0000-0002-8612-2994], Žák, Pavel [0000-0003-4465-5343], Cengiz Seval, Guldane [0000-0001-9433-2054], Bonuomo, Valentina [0000-0001-6491-8337], Mayer, Jiří [0000-0003-0567-9887], López-García, Alberto [0000-0002-5354-5261], Sacchi, Maria Vittoria [0000-0001-8133-3357], Booth, Stephen [0000-0003-2687-0234], Ciceri, Fabio [0000-0003-0873-0123], Nunes-Rodrigues, Raquel [0000-0002-8347-4281], Ammatuna, Emanuele [0000-0001-8247-4901], Obr, Aleš [0000-0002-6758-3074], Herbrecht, Raoul [0000-0002-9381-4876], Shwaylia, Hawraa [0000-0002-4098-6092], Sciumè, Mariarita [0000-0001-7958-4966], Essame, Jenna [0000-0003-0926-5577], Batinić, Josip [0000-0001-5595-9911], Gonzaga, Yung [0000-0003-1416-2118], Regalado-Artamendi, Isabel [0000-0002-9673-9015], Karlsson, Linda Katharina [0000-0003-3317-7550], Shapetska, Maryia [0000-0002-1223-9161], El-Ashwah, Shaimaa [0000-0003-2210-1534], Çolak, Gökçe Melis [0000-0002-7662-7454], Dragonetti, Giulia [0000-0003-1775-6333], Rinaldi, Amelia [0000-0002-8211-5076], Ramón, Cristina de [0000-0002-8167-6410], Cornely, Oliver A. [0000-0001-9599-3137], Institut Català de la Salut, [Pagano L] Hematology, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS – Università Cattolica del Sacro Cuore, Rome, Italy. Università Cattolica del Sacro Cuore, Rome, Italy. [Salmanton-García J] Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Excellence Center for Medical Mycology (ECMM), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. Cologne Excellence Cluster On Cellular Stress Responses in Aging Associated Diseases (CECAD), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. [Marchesi F] Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. [Busca A] Stem Cell Transplant Center, AOU Citta’ Della Salute E Della Scienza, Turin, Italy. [Corradini P] University of Milan and Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. [Hoenigl M] Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, USA. Clinical and Translational Fungal Working Group, University of California San Diego, La Jolla, CA, USA. Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Graz, Austria. [Cabirta A, Izuzquiza M] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, Hematology, Salmanton-García, Jon, Klimko, Nikolay, Víšek, Benjamin, Weinbergerová, Barbora, Córdoba, Raúl, Doesum, Jaap van, Čerňan, Martin, Jakšić, Ozren, Magliano, Gabriel, Kulasekararaj, Austin G., Valković, Toni, Poulsen, Christian Bjørn, Glenthøj, Andrea, Ráčil, Zdeněk, Piukovics, Klára, García-Vidal, Carolina, Principe, Maria Ilaria del, Jonge, Nick de, Ormazabal-Vélez, Irati, Antić, Darko, García-Sanz, Ramón, Biernat, Monika, Schönlein, Martin, Calbacho, María, Méndez, Gustavo-Adolfo, Duléry, Rémy, Žák, Pavel, Cengiz Seval, Guldane, Mayer, Jiří, López-García, Alberto, Obr, Aleš, Sciumè, Mariarita, Batinić, Josip, Çolak, Gökçe Melis, Ramón, Cristina de, and Universidad de Sevilla. Departamento de Medicina
Subjects: [SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Male, Cancer Research, MESH: Registries, Epidemiology, MESH: Hospitalization, Hematological malignancies, Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores], MESH: Aged, 80 and over, MESH: Risk Factors, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Risk Factors, Malalties - Factors de risc, Risk of mortality, Medicine and Health Sciences, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], 80 and over, Medicine, MESH: COVID-19, Registries, Sang - Malalties - Complicacions, RC254-282, Cause of death, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina, MESH: Aged, Aged, 80 and over, Hematology, MESH: Middle Aged, Mortality rate, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Myeloid leukemia, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Middle Aged, CANCER, Europe, Hospitalization, Intensive Care Units, Oncology, MESH: Young Adult, Hematologic Neoplasms, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Female, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Infektologija, Life Sciences & Biomedicine, Adult, medicine.medical_specialty, [SDV.CAN]Life Sciences [q-bio]/Cancer, COVID-19, EHA, Pandemic, Aged, Humans, SARS-CoV-2, Young Adult, técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], [SDV.CAN] Life Sciences [q-bio]/Cancer, Intensive care, Internal medicine, Diseases of the blood and blood-forming organs, MESH: SARS-CoV-2, neoplasias::neoplasias por localización::neoplasias hematológicas [ENFERMEDADES], Molecular Biology, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine, pandemic, hematological malignancies, epidemiology, MESH: Humans, Science & Technology, business.industry, Myelodysplastic syndromes, Research, MESH: Adult, Neoplasms::Neoplasms by Site::Hematologic Neoplasms [DISEASES], medicine.disease, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Infectology, Settore MED/15, MESH: Male, Settore MED/15 - MALATTIE DEL SANGUE, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, COVID-19 (Malaltia) - Diagnòstic, MESH: Intensive Care Units, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], MESH: Europe, RC633-647.5, business, MESH: Female, Other subheadings::Other subheadings::/complications [Other subheadings], MESH: Hematologic Neoplasms
Abstract: Background Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value, EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223).
Published: 2021

43. Balloon-Expandable or Self-Expandable Valves in Valve-in-Valve Transcatheter Aortic Valve Implantation?

Author: Nieuwkerk, Astrid, Eduard Fernandez-Nofrerias, Tchetche, Didier, Brito, Fabio, Barbanti, Marco, Kornowski, Ran, Latib, Azeem, D Onofrio, Augusto, Ribichini, Flavio, Tello, Vicente Mainar, Dumonteil, Nicolas, Baan, Jan, Abizaid, Alexandre, Sartori, Samantha, D Errigo, Paola, Tarantini, Giuseppe, Lunardi, Mattia, Orvin, Katia, Pagnesi, Matteo, Ghattas, Angie, Dangas, George, Mehran, Roxana, and Delewi, Ronak
Published: 2021

44. Inter-company consent document ANMCO / GISE / SICCH: Antithrombotic therapy in patients undergoing surgery and / or interventional heart valve: how to treat complications

Author: Patanè, Leonardo, Di Lenarda, Andrea, Aspromonte, Nadia, Bianca, Innocenzo, Capranzano, Piera, Di Eusanio, Marco, Di Fusco, Stefania, Di Tano, Giuseppe, Gabrielli, Domenico, Garatti, Andrea, Geraci, Giovanna, Gerometta, Piersilvio, Miceli, Antonio, Montalto, Andrea, Musumeci, Francesco, Musumeci, Giuseppe, Nardi, Federico, Parolari, Alessandro, Pino, Paolo Giuseppe, Rubino, Antonino Salvatore, Savini, Carlo, Troise, Giovanni, Tarantini, Giuseppe, Urbinati, Stefano, Varbella, Ferdinando, Gulizia, Michele Massimo, Patanè, Leonardo, Di Lenarda, Andrea, Aspromonte, Nadia, Bianca, Innocenzo, Capranzano, Piera, Di Eusanio, Marco, Di Fusco, Stefania, Di Tano, Giuseppe, Gabrielli, Domenico, Garatti, Andrea, Geraci, Giovanna, Gerometta, Piersilvio, Miceli, Antonio, Montalto, Andrea, Musumeci, Francesco, Musumeci, Giuseppe, Nardi, Federico, Parolari, Alessandro, Pino, Paolo Giuseppe, Rubino, Antonino Salvatore, Savini, Carlo, Troise, Giovanni, Tarantini, Giuseppe, Urbinati, Stefano, Varbella, Ferdinando, and Gulizia, Michele Massimo
Subjects: Platelet aggregation inhibitor, Cardiac surgical procedure, Heart valve prosthesi, Blood coagulation, Cardiac catheterization
Abstract: Continuous improvement of technologies, devices and drugs needs a renewal and update of current recommendations and guidelines on antithrombotic strategies, especially in those fields where literature lacks of established scientific evidences. Accordingly, the aim of this consensus statement is to provide support for antithrombotic therapy based on current guidelines and the most recent scientific evidences. After an overview on the currently available devices, the appropriate therapy according to type of procedure and implanted device is discussed. The occurrence of postoperative thromboembolic and/or hemorrhagic complications is analyzed, along with the appropriate diagnostic tools and therapeutic approach. A section is dedicated to counseling to pregnancy in women with heart valve prosthesis. Finally, the role of novel oral anticoagulants is discussed, and indications are provided for the management of patients undergoing surgery or interventional procedures on oral anticoagulation therapy. Continuous improvement of technologies, devices and drugs needs a renewal and update of current recommendations and guidelines on antithrombotic strategies, especially in those felds where literature lacks of established scientifc evidences. Accordingly, the aim of this consensus statement is to provide support for antithrombotic therapy based on current guidelines and the most recent scientifc evidences. After an overview on the currently available devices, the appropriate therapy according to type of procedure and implanted device is discussed. The occurrence of postoperative thromboembolic and/or hemorrhagic complications is analyzed, along with the appropriate diagnostic tools and therapeutic approach. A section is dedicated to counseling to pregnancy in women with heart valve prosthesis. Finally, the role of novel oral anticoagulants is discussed, and indications are provided for the management of patients undergoing surgery or interventional procedures on oral anticoagulation therapy.
Published: 2019

45. [Online Addenda: Italian certification for interventional cardiologists from the Italian Society of Interventional Cardiology (SICI-GISE)]

Author: Saia, Francesco, Bruno, Antonio Giulio, Franzone, Anna, Mojoli, Marco, Mattesini, Alessio, Masiero, Giulia, Costa, Francesco, Rigattieri, Stefano, La Manna, Alessio, Castiglioni, Battistina, Limbruno, Ugo, Mauro, Ciro, Tarantino, Fabio, Musumeci, Giuseppe, Esposito, Giovanni, Tarantini, Giuseppe, Saia, Francesco, Bruno, Antonio Giulio, Franzone, Anna, Mojoli, Marco, Mattesini, Alessio, Masiero, Giulia, Costa, Francesco, Rigattieri, Stefano, La Manna, Alessio, Castiglioni, Battistina, Limbruno, Ugo, Mauro, Ciro, Tarantino, Fabio, Musumeci, Giuseppe, Esposito, Giovanni, and Tarantini, Giuseppe
Subjects: na
Abstract: na
Published: 2019

46. sj-pdf-1-eso-10.1177_2396987320939804 - Supplemental material for An assessment of annual procedure volumes and therapy adoption of transcatheter closure of patent foramen ovale in four European countries

Author: Pietzsch, Jan B, Geisler, Benjamin P, Daniels, Matthew J, Busca, Rachele M, Tarantini, Giuseppe, Søndergaard, Lars, and Kasner, Scott E
Subjects: FOS: Clinical medicine, Cardiology, Medicine, 110904 Neurology and Neuromuscular Diseases
Abstract: Supplemental material, sj-pdf-1-eso-10.1177_2396987320939804 for An assessment of annual procedure volumes and therapy adoption of transcatheter closure of patent foramen ovale in four European countries by Jan B Pietzsch, Benjamin P Geisler, Matthew J Daniels, Rachele M Busca, Giuseppe Tarantini, Lars Søndergaard and Scott E Kasner in European Stroke Journal
Published: 2020
Full Text: View/download PDF

47. Additional file 4 of Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial

Author: Tarantini, Giuseppe, Mojoli, Marco, Varbella, Ferdinando, Caporale, Roberto, Rigattieri, Stefano, Andò, Giuseppe, Cirillo, Plinio, Pierini, Simona, Santarelli, Andrea, Sganzerla, Paolo, Cesare, Nicoletta De, Limbruno, Ugo, Lupi, Alessandro, Ricci, Roberto, Cernetti, Carlo, Favero, Luca, Saia, Francesco, Roncon, Loris, Gasparetto, Valeria, Ferlini, Marco, Ronco, Federico, Ferri, Luca, Trabattoni, Daniela, Russo, Alessandra, Guiducci, Vincenzo, Penzo, Carlo, Tarantino, Fabio, Mauro, Ciro, Marchese, Alfredo, Castiglioni, Battistina, Manna, Alessio La, Martinato, Matteo, Gregori, Dario, Angiolillo, Dominick J., and Musumeci, Giuseppe
Abstract: Additional file 4. Appendix 1
Published: 2020
Full Text: View/download PDF

48. Additional file 3 of Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial

Author: Tarantini, Giuseppe, Mojoli, Marco, Varbella, Ferdinando, Caporale, Roberto, Rigattieri, Stefano, Andò, Giuseppe, Cirillo, Plinio, Pierini, Simona, Santarelli, Andrea, Sganzerla, Paolo, Cesare, Nicoletta De, Limbruno, Ugo, Lupi, Alessandro, Ricci, Roberto, Cernetti, Carlo, Favero, Luca, Saia, Francesco, Roncon, Loris, Gasparetto, Valeria, Ferlini, Marco, Ronco, Federico, Ferri, Luca, Trabattoni, Daniela, Russo, Alessandra, Guiducci, Vincenzo, Penzo, Carlo, Tarantino, Fabio, Mauro, Ciro, Marchese, Alfredo, Castiglioni, Battistina, Manna, Alessio La, Martinato, Matteo, Gregori, Dario, Angiolillo, Dominick J., and Musumeci, Giuseppe
Abstract: Additional file 3. Case report form
Published: 2020
Full Text: View/download PDF

49. Additional file 1 of Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial

Author: Tarantini, Giuseppe, Mojoli, Marco, Varbella, Ferdinando, Caporale, Roberto, Rigattieri, Stefano, Andò, Giuseppe, Cirillo, Plinio, Pierini, Simona, Santarelli, Andrea, Sganzerla, Paolo, Cesare, Nicoletta De, Limbruno, Ugo, Lupi, Alessandro, Ricci, Roberto, Cernetti, Carlo, Favero, Luca, Saia, Francesco, Roncon, Loris, Gasparetto, Valeria, Ferlini, Marco, Ronco, Federico, Ferri, Luca, Trabattoni, Daniela, Russo, Alessandra, Guiducci, Vincenzo, Penzo, Carlo, Tarantino, Fabio, Mauro, Ciro, Marchese, Alfredo, Castiglioni, Battistina, Manna, Alessio La, Martinato, Matteo, Gregori, Dario, Angiolillo, Dominick J., and Musumeci, Giuseppe
Abstract: Additional file 1. SPIRIT checklist – DUBIUS study protocol.
Published: 2020
Full Text: View/download PDF

50. Additional file 5 of Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial

Author: Tarantini, Giuseppe, Mojoli, Marco, Varbella, Ferdinando, Caporale, Roberto, Rigattieri, Stefano, Andò, Giuseppe, Cirillo, Plinio, Pierini, Simona, Santarelli, Andrea, Sganzerla, Paolo, Cesare, Nicoletta De, Limbruno, Ugo, Lupi, Alessandro, Ricci, Roberto, Cernetti, Carlo, Favero, Luca, Saia, Francesco, Roncon, Loris, Gasparetto, Valeria, Ferlini, Marco, Ronco, Federico, Ferri, Luca, Trabattoni, Daniela, Russo, Alessandra, Guiducci, Vincenzo, Penzo, Carlo, Tarantino, Fabio, Mauro, Ciro, Marchese, Alfredo, Castiglioni, Battistina, Manna, Alessio La, Martinato, Matteo, Gregori, Dario, Angiolillo, Dominick J., and Musumeci, Giuseppe
Abstract: Additional file 5. National Medicines Agency approval
Published: 2020
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

216 results on '"Tarantini, Giuseppe"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources